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There is little data on immuno-suppressant administration and prescribing to transplant 
patients. It was considered a high risk area because errors in prescribing and administration of 
immuno-suppressants can potentially have serious consequences like graft loss, side effects 
and even death. The reality was however that the lack of data meant that no one knew whether 
this was an area for improvement or not. The need for data collection was recognised and the 
aim of this study was to develop and validate a tool to inform the analysis of the patient 
journey (Failure Mode Effect Analysis) and identify opportunities for quality improvement of 
immunosuppressant medication use. (Time did not allow for the FMEA to be conducted). 
Methods 
One-to-one semi structured interviews were conducted with clinical staff (2 pharmacists, 2 
nurses and 6 doctors) to explore their perceptions of high risk areas. A case study was done to 
define the patient journey and identify potential areas where the patient might be at risk of 
harm. Analysis of database of incident reports (from 2010) was conducted. Lastly, analysis of 
pharmaceutical care issues identified by clinical pharmacists (2 pharmacists) was done. 
Results 
Some of the areas identified by staff from interviews were; need for consistent education to 
patient by all healthcare professions, need for education of staff, communication with primary 
healthcare professions with regard to risk associated with immuno-suppressants, teamwork 
amongst the staff on the ward and documentation of interventions. A patient journey detailed 
where and when high risk processes could occur. The patient journey identified the following 
areas as high risk: nurses being busy, interrupted or not giving appropriate education. Patients 
being non-compliant in medications and follow-up meetings, doctors not having clear 
handwriting, doctors not writing the formulation of immuno-suppressant etc. Database 
analysis confirmed that Datix® was not a well used reporting system and incidents were 
mainly in the immuno-suppressant administration category. The incidents reported 
emphasised the need to follow safe use of medicines policy. Pharmaceutical care issues were 
not well documented and there were no consistent interventions to confirm particular high risk 
areas. 
Discussion 
The richest data came from interviews and highlighted actions that could be used to reduce 
risk of harm from immuno-suppressive drug therapy. The data collected can be used to 
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National Health Services (NHS) Lothian is part of NHS Scotland.  Health service is 
distributed in the country through fourteen regional NHS boards[1] where NHS Lothian is one 
of these fourteen. NHS Lothian is an important employer and has almost 28 000 staff which 
includes 15 000 nursing and midwifery staff and 2700 medical staff. NHS Lothian cares for a 
population of 800 000[2] locally but they also offer some specialist services to the rest of the 
country. Among some of the specialist services they provide are the kidney and liver and 
pancreas transplantations.  
Quality improvement and patient safety are both important focus points of NHS Scotland and 
this master thesis is part of the work to improve patient safety and minimise harm to patients, 
in this case; patients receiving solid organ transplantation. 
There are many definitions of harm.  
The British Medical Association supports the definition of harm as: 
“Adverse outcomes or injuries stemming from the provision of healthcare” [3] 
Another definition of the prevention of harm is:  
“Freedom from accidental or preventable injuries produced by medical care.”[4] 
The Scottish patient safety programme[5] (SPSP) aims to make the healthcare system reliable 
and safe. SPSP‟s objective is to improve the safety of hospital care across the country. SPSP 
is co-ordinated by [6]NHS Quality Improvement Scotland (NHS QIS) which seeks to improve 
the quality of patient care throughout the country. 
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SPSP states that [5]UK and international evidence indicates that 1 in 10 patients experience 
an adverse event in hospital where adverse events are defined as unintended consequences of 
care like for example a drug error. Research shows that 50% of adverse events can be avoided 
if rigorous patient safety processes are routinely followed. Adverse events can result in severe 
emotional, psychological and physical impact on patients, but the costs are also significant. 
Adverse events are estimated to cost NHS Scotland around £200 million each year in extra 
treatment and lost bed days.[7] The National Patient Safety Agency calculated that 
preventable medication errors cost the NHS more than £750 million each year in England. [8] 
This is money that could benefit countless patients and staff and optimise patient care if there 
was a way to minimise the costs associated with medication. 
 
Institute for Healthcare Improvement (IHI)[9] is an American based non-profit organisation. 
They work with health carers all over the world to test new models and motivate for change 
so that the best practice can be found and adopted by everyone. The IHI believe that everyone 
deserves safe and effective health care. The essence of the thinking is to share knowledge, 
collaborate and improve health and health care everywhere for everyone. In order to 
accomplish that, innovative ideas are the key to success.  
IHI defines adverse drug events as: 
“Harm to the patient from medications, whether or not the result of an error.” 
Conventional efforts to detect adverse events have focused on voluntary reporting and trying 
to investigate errors that do happen. According to IHI, public health researchers have 
established that only 10 to 20 percent of errors are ever reported and, of those, 90 to 95 % 
cause no harm to patients [10]. The remaining ones can be the cause of significant harm and 
high costs however. There is a need for a system that not only detects errors and allows for 
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staff to report without it taking up too much of their time, but also encourages no-blame 
reporting so that staff are not afraid to report errors they have made themselves. There needs 
to be an emphasis on how important it is to report errors in order to be able to investigate 
them and make changes to minimise them. There is no current system in place in NHS 
Scotland that will let people detect and report errors within a time limit without resulting in 
blame. 
Williams[11] defines medication errors as: 
“Any error in the prescribing, dispensing, or administration of a drug, irrespective of whether 
such errors lead to adverse consequences or not” 
He states that medication errors are the single most preventable cause of harm to patients.  
The article also emphasises the causes of medication errors, one of them being that medical 
staff responsible for most of the prescribing in hospitals can be relatively inexperienced and 
so mistakes are more likely to happen. Electronic prescribing can be a solution to eliminate 
the risks of prescribing errors. It also has its weaknesses however; although some sources of 
errors are eliminated, others are encountered. 
1.2 Why transplant was chosen as a project topic 
The transplant ward was chosen as a project topic because immuno-suppressants were 
considered high risk medicines and errors in administration and prescribing of these 
medicines could result in serious consequences. Some of the consequences include graft 
rejection or toxicities such as nephrotoxicity, hepatoxicity, disturbances in glucose 
metabolism (can lead to diabetes), neurotoxicity, malignancies, increased risk of infection and 
gastrointestinal disturbances in terms of nausea, vomiting and diarrhoea which again can alter 
uptake of drugs from intestine. The quality improvement (QIT) team of the transplant ward 
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recognised immuno-suppressant medications as high risk and suggested the area of interest to 
the lead pharmacist at RIE and the senior pharmacist at the liver transplant ward at the RIE.  
The NHS patient safety website defines high risk medication as: 
“High risk medicines are medicines that are most likely to cause significant harm to the 
patient, even when used as intended. The Institute for Safe Medication Practices (ISMP) 
reports that incident rates with this group of medicines may not necessarily be higher than 
with other medicines, but when incidents occur the impact on the patient can be 
significant.”[12] 
Typically examples of drugs considered high risk medications are anticoagulants (i.e. warfarin 
and heparin) opiates and insulin[13]. Immuno-suppressants do however fit under the 
definition in the aspect that they can cause significant harm even when used as intended. 
There are a lot of individual patient factors that determine this. Immunosuppressant therapy in 
transplant patients is a complex matter as many of the drugs may result in severe side effects. 
Many of these drugs are also subject to drug interactions.  
Although there are many potential error sources and serious consequences if immuno-
suppressants are prescribed or administered wrongly, there is very little data and few studies 
that have actually been carried out on this particular topic in this context. Therefore the QIT 
and pharmacists at the RIE along with the investigator recognised the need for data collection 





Datix[14] is a software programme that aims to help healthcare workers increase patient 
safety and reduce harm to patients. Today more than 70 % of the UK NHS use Datix. Datix  is 
a safety improvement tool [14] intended to improve patient safety. Staff can voluntarily report 
incidents on Datix. The reporter describes the situation and fills out a form that allows details 
of the situation to be given and explained. The incident is investigated by the appropriate 
person i.e. the charge nurse or section head who allocates the grade of severity (low, medium 
or high). However, it is a known weakness of Datix that it is not used consistently in hospitals 
as Datix relies on staff to report all incidents in order to be a reliable tool for investigating 
trends. Voluntary reporting and lack of time and incentive to report means that incidents are 
rarely recorded on Datix which makes the few reports that do come in, impossible to 
generalise or conclude anything from. One of the problems may be the fear of blame between 
staff. Datix reporting is often associated with blame instead of focusing on lesson learned 
from the reports. It is important to focus on medication error reporting as no-blame processes 
that are important to improve patient safety and minimise harm to patients.  
A project carried out by pre-registration pharmacist trainees in NHS Lothian in 2008 found 
that[15]: 
“Over the total observation period (7 weeks) 3 incidents were documented on the hospital 
reporting system and 261 medication related incidents were observed by the investigators in 
the seven specialties.” 
A system should ideally allow people to easily report incidents in a reasonable amount of 
time, learn from them and be able to discuss improvements without feeling a sense of guilt or 
blame. There is clearly a lack of such a system. In order for an incident reporting system to be 
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successful, the people using it need to learn from the mistakes and also be motivated to see 
the importance of this. Staff need to be provided with sufficient education and guidance as to 
what types of incidents or near-misses should be reported and how to best describe it so others 
can learn and benefit from it.  
A study[16] done in north east of Scotland on Datix incident reports showed that over a 46 
month period 80 % of reports were made by nursing and midwifery staff. The medical and 
dental profession reported the lowest number of incidents. This is an indication that Datix 
reports regard for the most part administration errors as nurses will pick these up. Though it 
can be argued that it is not only doctors who can detect prescribing errors, the errors that 
happen in prescribing might never be reported by doctors and so are largely unknown. The 
study also states that; 
”Approximately 20 % of deaths from adverse events are related to medication incidents, 
costing the NHS an additional £500 million annually. Less than 5% of adverse events are 
reported.” [16] 
Quality improvement and patient safety projects rely on there being data to show the status 
quo and what is actually going wrong in order to improve upon this. This is however very 
difficult when most incidents remain unreported. The result being that one can only 
approximate if and how many errors are occurring, but there are no actual numbers for it. 




1.4 One-stop dispensing and self administration 
1.4.1 One-stop dispensing 
One-stop dispensing[17], also known as „dispensing for discharge‟ essentially means to 
combine in-patient and discharge dispensing into one single process. Along with the use of 
patients own drugs (POD) this results in quicker discharge by reducing dispensing time, 
reduced drug errors and reduced wastage and hence costs. The use of POD may contribute to 
more accurate drug history as patients are familiar with the packs and can easier identify 
drugs and doses.  
1.4.2 Self administration  
Specific for the transplant ward is self administration which is a three stage process whereby a 
transplant patient is ultimately allowed to administer his or her own medicines after a nurse or 
pharmacist has assessed them, provided authorisation and the patient has satisfied a number of 
compliance checks. Patients are also encouraged to bring their medication with them when 
they are admitted to hospital and so they can keep taking their own drugs as well. This is 
called use of patients own drugs (POD).  Use of POD contributes to the overall aim of letting 
more patients self administer their own drugs. Patients will receive education beforehand from 
clinical staff about self administration and their drugs and are given the chance to ask any 
questions that might come up. 
The self administration forms are filled out by nurses or pharmacists includes questions 
concerning whether the patients has received education, is on intravenous drugs, is confused, 
has had a previous overdose, can open bottles etc. The medications the patient uses are placed 
in a locker beside their bed, and the nurses have the key to it. The patients normally start on 
stage three during self administration. During stage two the nurse has the key to the locker, 
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opens the locker, allows the patient to take their medications and do daily checks of the 
content of the locker. At stage one the patients have the key to their locker and the nurses do 
weekly compliance checks. The self administration in the transplant ward applies mostly to 
oral drugs. 
The patients receive a medication reminder book known as „the green book‟ before they are 
discharged from hospital. This book contains a list of all the patient‟s medications, and a few 
notes on how to take them. It should ideally be updated every time there is a dose change to 
any medications. Patients are encouraged to bring the green book to every clinic visit. 
Self administration in the transplant unit is aimed at preparing patients for going home and 
giving them the opportunity to get any questions answered whilst still in the hospital setting. 
The patient is meant to feel more confident when going home and should know all they need 
to know about medications, dosages and side effects. In transplant patients this is an important 
issue especially for liver transplant patients where many of them have not been on many 
medicines at all pre-transplant, whereas post-transplant they will leave with several different 
medications that are all vital to the success of their graft survival. Going home and 
remembering everything might prove to be a bigger challenge than patients first imagine it to 
be whilst in the hospital setting. Drug compliance is such an important part of a transplanted 
patients‟ health and that is emphasised throughout a transplant patient‟s journey.  
1.5 Liver, kidney and pancreas transplantation 
Success rates for organ transplantation the last few years have improved remarkably and 
organ transplantation now saves many lives. For kidney transplant patients who no longer 
need dialysis, it makes life easier and increases quality of life.  
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1.5.1 Liver transplantation 
Liver transplantation [18] success rates have increased the past years but there is no 
equivalent increase in cadaveric donors (i.e. organ from an organ donor who has died 
resulting in brain stem death) and so the number of patients on waiting list keeps increasing 
and some patients die whilst waiting for an organ. The main problem remaining is the 
shortage of cadaveric donors. One of the solutions to this has been living donor 
transplantations where often a relative donates part of his or her liver to the recipient. Liver 
transplantations are matched based on size of organ and blood group. However not all people 
have someone willing to donate part of their liver or fill the criteria for living donor 
transplantation and living donor transplantations remain uncommon at the RIE. Shortage of 
cadaveric donors is still the major issue with liver transplantations. 
1.5.2 Kidney transplantation 
Kidney transplant has changed the life and future of patients with kidney failure. Before, 
dialysis was the only option but now a kidney transplant can restore health. The kidney can 
come from a cadaveric donor or a close relative if it is a living donor transplantation. As for 
any organ transplant, there is also here a shortage of organs. Kidneys are allocated by blood 
and tissue type. 
1.5.3 Pancreas transplantation 
Pancreas transplantations are not as common as liver and kidney transplant. It is often an 
option for patients that have diabetes and renal failure and need a kidney and pancreas 
transplantation at the same time. Pancreas transplantation is only suitable for type 1-diabetes 
is allocated by blood group. 
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1.6 Immunosuppressant medication 
1.6.1 Background 
The immune system is the body‟s natural defence. Transplanted cells from a donated organ or 
graft are considered foreign and unfamiliar and so the body‟s immune system will seek to 
destroy them. Therefore immuno-suppressants are needed to prevent the body from rejecting 
the new organ. After transplantation, they have to be taken every day for the rest of the 
patients‟ life. Immunosuppressant medications[19] are hence at the core of an successful 
organ transplantation. If blood levels of immuno-suppressants are too high, side effects and 
infections can occur. If levels are too low, organ rejection may occur. Optimal dosing and 
combination of immuno-suppressants is key and it needs to be finely tuned. Some of the 
immuno-suppressants have a narrow therapeutic index and show significant variability in 
blood concentrations between individuals. Therefore blood monitoring of some of the 
immuno-suppressants (tacrolimus and ciclosporin) plays a big part of the adjustment of the 
dosage regimen. Immuno-suppressants can cause serious side effects even at the right doses 
which is why it is important that patents understand how vital it is for them to be compliant if 
they do experience side effects. 
During the first few months after organ transplantation risk of rejection is at its highest and 
hence so are the doses of the immuno-suppressants. To avoid unnecessary high doses of 
immuno-suppressants and hence side effects, a dosage regimen of several different immuno-
suppressants are used. This lowers risk of serious side effects instead of using one single 
immuno-suppressant at a very high dose, several with different modes of action are used at 
lower doses. The risk of infection is also at this point highest as the high doses of immuno-
suppressant medications lower the ability of the immune system to fight of infections. The 
patients are monitored very closely for signs of infection. 
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All immuno-suppressant medication used in transplant can be considered high risk 
medication. Transplant patients are a complex group of patients that have a range of different 
co-morbidities and patients can be of all ages. Also, graft rejection is dependent on many 
factors including immune response which is very individual. This makes drug therapy and 
development of standard protocols for therapy a complex issue. Nonetheless this group of 
patients need to be especially compliant as non-compliance can potentially lead to organ 
rejection, severe side effects and even death. 
1.6.2 Antiproliferative immuno-suppressants 
Azathioprine (AZA) is widely used for transplant recipients. It is metabolized to 6-
mercaptopurine which is further converted to active 6-thioguanine nucleotides. These 
metabolites are incorporated into DNA where they inhibit purine nucleotide synthesis. Blood 
tests and monitoring for signs of bone marrow suppression are essential in long-term 
treatment with AZA. Two serious side effects are bone marrow suppression and 
hepatotoxicity. The side effects are dose dependent. 
Mycophenolate mofetil (MMF) is metabolised to mycophenolic acid which has a more 
selective mode of action than AZA. It inhibits purine synthesis but it is specific to 
lymphocytes. It is licensed for the prophylaxis of acute organ rejection in renal, hepatic or 
cardiac transplantation when used in combination with ciclosporin and corticosteroids and is 
thought to be CNI sparing so a lower dose of CNI‟s can be used. Common side effects include 
diarrhoea, bloating, nausea, heartburn and high blood pressure. 
For liver transplantation the out-patient guidelines[19] state that MMF and azathioprine are 
similar drugs but MMF is a more potent immuno-suppressant that azathioprine. MMF is used 
in three situations at the SLTU[19]: 
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1) “In patients with early chronic rejection, in combination with tacrolimus. 
In patients with renal impairment to allow either: 
2) Replacement of CNI with MMF and Prednisolone 
3) Dose reduction of CNI in combination with MMF” 
From the website for Edinburgh Renal Unit (EdRen) [20] all patient receiving kidney and/or 
pancreas transplantation are given MMF unless they are unable to tolerate it, in which case 
AZA can be given. If patients are considered low risk recipients then MMF can be replaced 
with the less potent AZA in the long term immuno-suppression drug regimen. 
1.6.3 Calcineurin inhibitors (CNIs) 
The CNIs are ciclosporin and tacrolimus and they are considered the cornerstones of immuno-
suppressive regimens. They have similar modes of action. They decrease T-cell activation by 
inhibiting calcineurin resulting in T-cells that are unable to induce an immune response. CNIs 
can result in kidney damage at particularly high doses. It is thought that the kidney damage in 
both CNIs has similar mechanisms. One proposed mechanism for this is [21] that ciclosporin 
causes reversible impairment of glomerular filtration and irreversible fibrosis.  
One proposed mechanism [22] for the nephrotoxicity resulting from CNI use is that it is the 
result of vasoconstriction of intra-renal vessels causing decreased renal blood flow.  
Another  study [23] done on “Calcineurin inhibitor-induced renal allograft nephrotoxicity” 
concludes the following:  
”Pathophysiologic mechanisms behind CI (calcineurin inhibitors) nephrotoxicity are only 
partially elucidated (...) the main effect responsible for toxicity still remains unsolved (...) 
Since CI remain, despite their nephrotoxic effect, the mainstay of immunosuppressive 
protocols, their use needs to be optimized. The main measure to prevent nephrotoxicity is the 
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effort to reduce systemic levels and keep local renal exposure to CI and their metabolites as 
low as possible.” [23] 
Other troublesome concerns with both of these drugs are headaches, tremors, hypertension 
and hyperkalemia [22]. In addition tacrolimus can increase blood sugar and result in 
diabetes[24]. Ciclosporin can cause high blood pressure, increased hair growth and 
sore/swollen gums [25]. 
Tacrolimus is now considered the first line agent for kidney, pancreas and liver 
transplantation at the RIE. From the liver in-patient protocol[26] for liver transplants at the 
RIE it is stated: 
“Prograf (tacrolimus) is to be prescribed following liver transplantation.” 
At the renal unit website, EdRen [20], it is stated under prograf/advagraf (tacrolimus) that it 
is: 
“The lead agent in standard triple therapy for all patients.” 
There have been many studies done on tacrolimus versus ciclosporin as the primary immuno-
suppressant and most show tacrolimus to be superior. One study [27] done on tacrolimus 
versus ciclosporin in liver transplanted patients showed tacrolimus to be superior in patient 
survival, graft survival, and preventing acute rejection. However it did also show an increase 
in post-transplant diabetes. Another study[28] done on the same topic in patients transplanted 
for kidneys showed improved graft survival and prevention of rejection, but increased post-
transplant diabetes and other side effects. The authors conclusion was [28]: 
“Tacrolimus is superior to cyclosporin in improving graft survival and preventing acute 
rejection after kidney transplantation, but increases post-transplant diabetes, neurological and 
gastrointestinal side effects. Treating 100 recipients with tacrolimus instead of cyclosporin 
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would avoid 12 suffering acute rejection, two losing their graft but cause an extra five to 
become insulin-requiring diabetics.” [28] 
An important factor about these agents is that they come in a variety of different formulations 
which are not bioequivalent. It is important for patients and healthcare staff not to confuse 
these with each other as switching between them should only be done under close monitoring 
by transplant specialist. Although not as much used at the RIE, ciclosporin comes as 
Sandimmune, Neoral and generic formulation. The two formulations of tacrolimus most 
frequently encountered at the RIE are Prograf and Advagraf. Prograf is an immediate release 
formulation taken twice daily. Advagraf is a prolonged release formulation that is taken once 
daily. For liver transplantation at RIE as stated above, Prograf is prescribed following 
transplantation according to the in-patient protocol. 
From EdRen.org: 
“Prograf will be used in the initial post-operative period. Patients can be switched to Advagraf 
once stable levels have been achieved, usually in the outpatient clinic.” 
1.6.4 Corticosteroids and other immuno-suppressants 
The use of corticosteroids is kept to a minimum or eliminated because of the long-term side 
effects [22]. However, they still remain powerful immuno-suppressants and are frequently 
used in acute rejection and in preventing rejection. They do however have serious side effects 
like irritation in the stomach, weight gain, rounded face, thinning of skin and bones 
(osteoporosis) and hyperglycaemia (diabetes) and so effort has been made to minimise the 
use. 
Basiliximab is a monoclonal antibody that prevents T-lymphocyte proliferation; it is used for 
prophylaxis of acute rejection in allogenic renal transplantation. It is licensed with ciclosporin 
and corticosteroid immuno-suppression regimens. At the RIE it is used in combination with 
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tacrolimus for induction therapy; it is given in two doses, first at the time of transplant and the 
next dose after four days. 
All kidney/pancreas transplanted patients at RIE receive basiliximab. For liver transplanted 
patients the in-patient protocol[26] chapter 7.2 states the following about basiliximab and 
when it is used: 
“BASILIXIMAB: This interleukin-2 receptor antagonist will be given in elective patients 
with serum creatinine > 150 micromol/l or eGFR < 40 ml/min.” 
In the liver unit, basiliximab is used in patients with renal dysfunction to allow delayed 
introduction of tacrolimus which is more nephrotoxic than basiliximab. 
Sirolimus is a non-calcineurin inhibiting immuno-suppressant only licensed for renal 
transplantation. It is also used in liver transplanted patients. It inhibits T-cell activation via 
suppression of proliferation driven by interleukin 2 (IL-2) and interleukin 4 (IL-4). 
Interleukins are a group of cytokine signalling molecules vital to normal immune response. 
The main benefit with sirolimus is that it lacks the nephrotoxicity that is an issue for the 
calcineurin inhibitors. 
1.6.5 Drug interactions 
Drug interactions are major focus with immuno-suppressants. The most common interactions 
are between CNI‟s and other drugs metabolised in the liver via the CYP3A4 enzyme system. 
Common interactions are listed in the out-patient protocol for liver patients and include 
interactions of CNI‟s with erythromycin, fluconazole, clarithromycin and amiodarone. Most 
of the drugs used in transplant are specialised and not used frequently in other conditions. The 
GPs take on some of the non-specialist prescribing for the transplant patient in the community 
setting after transplantation and drug interactions remains a potential problem. The GPs need 
to work in close contact with the transplant doctors in order to assure that no harm comes to 
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the patient when new drugs are introduced. Standard drugs used even for minor illnesses can 
potentially interact with many of the immuno-suppressants, and the GPs need to be informed 
about this in order to avoid drug interactions. The GPs get a copy of the discharge letter and 
can access shared care protocols. The GPs also get clinic letters after each clinic visit. This 
includes a list of medications.  
1.7 Principles of the Failure Modes Effect Analysis (FMEA)[29] 
The FMEA is a tool to evaluate a process that can be used in a variety of different settings. It 
helps identify where the weaknesses (failure points) are, assess these weaknesses and get 
ideas for improvement so the process is less likely to fail. FMEA is a method adopted by the 
SPSP to assess a process. As it is a fairly new method of improving quality, there is little data 
on the exact long term benefits of doing an FMEA. A PhD done by Nada Ates Shebl[30] in 
2010 confronted the issue of promoting patient safety using the FMEA. The author‟s 
conclusion was that the FMEA was: 
“...FMEA is a useful took to aid multidisciplinary groups in mapping and understanding a 
process of care. However, it is not a valid or reliable tool for identifying the failures that can 
occur or scoring the severity, probability and detectability. Healthcare organisations should 
not solely depend on their FMEA results to ensure patient safety.” [30] 
The author did state that the FMEA was subjective and depended upon the specific 
multidisciplinary team involved, which are known weaknesses of this method. 
Another study [31] published by the British Journal of Clinical Pharmacy in 2009 used the 




”FMEA was found to be an effective tool for identifying potential areas of risk in the use of 
rituximab, and the methodology could be applied to other high risk medicines.”[31] 
 In this project, the FMEA is thought to be part of the overall data collection and is not meant 
to be the only method relied on. 
The steps in the process of an FMEA are: 
1) Select a process to evaluate with FMEA this is usually a high risk process 
2) Recruit a multidisciplinary team 
3) Have the team meet together to list all of the steps in the process 
4) Have the team list failure modes and causes 
5) For each failure mode, have the team assign a numeric value (known as the Risk Priority 
Number, or RPN) for likelihood of occurrence, likelihood of detection, and severity 
6) Evaluate the results 
7) Use RPNs to plan improvement efforts 
 
The FMEA was chosen as a method for evaluating the process of prescribing and 
administering of immuno-suppressants, considered to be high risk medications. Traditionally 
high risk medications are the ones considered in chapter 1.2, but in this project immuno-
suppressants were considered high risk medications. Although they are not traditionally 
thought of in this context, they do fit under the definition in chapter 1.2. 
The FMEA focuses on the process and on what could go wrong instead of focusing on who 
may allow for something to go wrong. In that way the no-blame aspect is at the centre of 
attention. By doing an FMEA one can put measures in place to prevent failures from 





However, there are weaknesses to the FMEA approach. The most important weakness being 
as mentioned above, that the FMEA is a subjective way of risk assessing. The process is 
scored in terms of risk assessment by numeric values set by the different people involved in 
the FMEA team. The scores of high risk areas are therefore very subjective and rely on each 
individual in the group coming to a consensus. This is why it is useful to have a 
multidisciplinary team, so different grades of all types of staff involved, are included. This 
will make the final scores based on a broad variety of opinions of staff and in that way give a 
well rounded view of the process and help identify all areas of risk in the process. Different 
views from different professions on the same process are taken into account by using a 
multidisciplinary team. 
The FMEA‟s strength lay in carefully identifying which people to include and getting them to 
think thoroughly through the process before scoring each step. It also relies on that the fact 
that the members of staff selected are motivated for change and not afraid to identify 
weaknesses in the process. 
1.8 Potential high risk areas in administration and prescribing of immuno-
suppressants 
Prescribing on the transplant ward at the RIE is done for the most part by middle grade 
doctors however it is done under close supervision of senior doctors.  Electronic prescribing is 
not in place at the RIE so there is much relying on clear hand writing, giving written 
information and comments on kardex in an understandable way. Nurses rely on prescriptions 
to be clear in order for misunderstandings and errors to be avoided. 
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Medicines administration can be considered a potential high risk area. Nurses are understaffed 
at times and they have little time to complete tasks. A lot of people rely on nurses and they 
have many responsibilities on the ward. There are always people asking questions whether it 
be relatives of patients or other staff and this can be a source of distraction and ultimately lead 
to errors. Nurses getting distracted from what they were initially doing can lead to patients not 
receiving medications at the right time. Administering patient‟s medicines takes a lot of 
concentration to rule out any potential mistakes. Nurses are trained and should follow the 
NHS Lothian Safe Use of Medicines Policy and Procedures[32]. Interruptions often cause 
lapse in concentration which can lead to errors and processes have been put in place to 
minimise these interruption such as the tabards that the transplant wards have now introduced. 
The nurses now wear red vests called tabards which say; Do not disturb. Nurse on drug 
round. This is a measure put in place to minimise chances of nurses making mistakes whilst 
on drug rounds. 
1.9 The model for improvement 
The model for improvement is a tool adopted by SPSP that can be used to help evaluate a 
process and identify areas for improvement. The model for improvement[33] is a tool 
intended to accelerate improvement. It consists of two parts. The first part is answering the 




Figure 1: Model for improvement and PDSA cycle[34] 
Answering these questions allows the people involved to set aims for what they‟re doing, set 
up specific measures to see if the change is leading to improvement, and recognising the 
changes that are likely to lead to improvement. 
The second part is the Plan-Do-Study-Act cycle (PDSA). This is a test to check a change by 
planning it, trying it, observing the results and acting on what is learned from it all. This 
project is considered the planning part of the PDSA-cycle. The rest of the cycle can be if the 
recommendations for improvements resulting from this project are implemented (do), then to 
see whether this made a difference (study) and lastly act on the results from the study (act). 
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2 Aims and objectives 
2.1 Aim 
Develop and validate a tool to inform the analysis of the patient journey (Failure Mode Effect 
Analysis) and identify opportunities for quality improvement of immunosuppressant 
medication use. 
2.2 Objectives 
1. Map the patient journey before and after transplantation and identify points which 
present risk of harm due to potential adverse events associated with 
immunosuppressant medication use. 
2. Characterise the harm assessment based on historical incident reports and recorded 
interventions. Expand the harm assessment using perceptions of clinical staff.  
3. Further characterise the assessment using data from prospective survey(s).  
4. Validate the FMEA tool by presentation of findings to an expert group. 
2.3 Subjects and settings 
2.3.1 Study design 
The study included semi-structured one to one interviews, database analysis of Datix incident 
reports, case note review and retrospective review of care issues documented by pharmacists. 
2.3.2 Subjects and settings 
The project team comprised the investigator Kinjal Patel, Moira Kinnear Head of Pharmacy 
Education, Research and Development and Lecturer in Clinical Practice, Katherine Davison 
the clinical pharmacist from the liver transplant ward, Scott Garden the lead pharmacist and 
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lastly Sara Dyrhaug fellow investigator. The parallel project carried out by Sara Dyrhaug was 
on the drug Valganciclovir used in transplant patients for prophylaxis and treatment in 
Cytomegalovirus disease. 
The project included wards 206 (transplant ward) and 117 (high dependency unit, HDU) at 
the Royal Infirmary of Edinburgh (RIE). All liver and simultaneous kidney and pancreas 
transplanted patients are in ITU (118) immediately after transplant operation and with no 
complications they are usually transferred to HDU after 24 hours. Kidney transplanted 
patients go to HDU post-operative. All patients are then transferred to the ward area (206) 
when their condition improves. If the patient is readmitted they might be admitted to other 
wards initially or to other hospitals if the transplant hospital is far away. Often they do 
however end up on the transplant ward no matter what their illness is because they are a 
specialised group of patients. 
The teams on the wards are multidisciplinary and consist of nine consultant surgeons, six 
consultant hepatologists and ten consultant nephrologists. Also in the wards are nurses, 
various grades of medical staff, transplant co-ordinators, a dietician, two pharmacists, a social 
worker, physiotherapists and psychiatrists who all work together to optimise patient care. 
Each week the team (there is one renal team and one liver team) that looks after the ward 
consist of a junior grade doctor, medical registrar, surgical registrar, consultant physician and 
consultant surgeon. There is one registrar attached to each team of the liver and kidney teams; 
one hepatologist registrar, one nephrologist registrar and one surgical registrar. The registrars 
rotate approximately every two months. One junior doctor is attached to each team and they 
rotate 4 weekly.  
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The doctors were classified as junior grade (Foundation Year one and Foundation Year two, 
Senior House Officer), middle grade (speciality registrars) and senior grade (consultants). 
Patient criteria for review of pharmaceutical care issue documentation: 
1. In-patients only 
2. Post-transplant only. Including patients readmitted for complications of any sort. 
3. Transplant patients must be on one of more of the following immunosuppressant 
medications: Tacrolimus, Ciclosporin, Prednisolone, Mycophenolate mofetil, 
Azathioprine, Sirolimus or Basiliximab 
Clinical staff criteria for participation in interviews: 
1. Included staff of different grades (senior and junior) 
2. Included staff with different duration of experience from the transplant wards 
3. Include nurses and doctors in interviews and multidisciplinary team 
4. Include the pharmacists from the transplant ward for interviews 
The doctors and nurses included in interviews consisted of a convenience sample of people 
who were available at the time allocated to the investigator. 
2.3.3 Ethics approval 
The transplant QIT suggested the area of interest to the liver transplant ward pharmacist and 
recognised the current lack of data around the project topic. 
The project involved no personal identifiable information about patients and staff. A copy of 
the protocol was sent to Alex Bailey (Scientific Officer, South East Scotland Research Ethics 
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Service). Based on that, the project was classified as service evaluation and did not need NHS 
research ethical review. Full letter attached in appendix 2. 
3 Methods 
3.1 Patient journey 
The investigator undertook a case study to illustrate the patient journey before and after 
transplantation to identify potential and actual drug related problems in immuno-suppressant 
drug therapy. Self administration and nurse administration were looked into as a potential risk 
where things can go wrong. One of the liver transplant patients admitted in the fall of 2010 
was selected by the transplant ward pharmacist. The investigator reviewed the clinical case 
notes and medicines charts and documented the patient journey in terms of chronological 
clinical management. No identifiable personal data was included (names, detailed history, 
personal information, full date of birth etc). To get a clear picture of what the patients‟ issues 
were and how staff dealt with it, the investigator attended ward rounds and multidisciplinary 
ward meetings where issues that had been encountered throughout the week were addressed 
and patients were discussed. Through this the interaction and collaboration between different 
health professions and the multidisciplinary teamwork became evident. In addition the 
investigator attended clinic visits to be able to get a clear picture of patients‟ issues regarding 
immuno-suppressants both before and after transplant. Also the clinic visits and ward 
meetings allowed the investigator to help map the process of the patient journey and see 
issues from both medical staff, nurses‟, pharmacists‟ and patients‟ point of view. To fill in any 
blanks, the investigator used in-patient and out-patient policies and protocols for the liver 
transplant ward, including information documentation. These contained detailed descriptions 
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of guidelines [19, 26]regarding the immuno-suppressant and issues related to them such as 
interactions, side effects, the GPs role, monitoring etc. 
3.2 Characterising the harm assessment 
3.2.1 Historical incident reports; Datix 
Harm was characterised by using historical Datix incident reports to identify which type of 
drug related problems were associated with immunosuppressant drug therapy, recognising the 
underreporting in the use of Datix.  The investigator emailed the person responsible for Datix 
reports on the transplant ward (206+117) and hardcopies of reports from 2010 were provided 
for analysis. The data for immuno-suppressants was extracted from all reports from this area. 
In addition the investigator and a fellow investigator observed when one of the pharmacists at 
the RIE completed a report. The pharmacist went through the process of filling out the reports 
and explained the steps. 
3.2.2 Staff perceptions; interviews 
Staff on the transplant ward were made aware of the project (and a parallel project) through 
presentation of the protocol(s) at a transplant ward meeting (appendix). Staff had an 
opportunity to express opinions and ideas about the project(s). The liver transplant ward 
pharmacist had sought approval from the transplant QIT whose comments were also included 
in the project design.  
A questionnaire was designed (appendix) for one-to-one structured interviews with a range of 
doctors and nurses from the transplant ward to gather their opinions about risks in the process 
of prescribing and administering of immuno-suppressant agents in patients having undergone 
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solid organ transplantation. The interview schedule took into consideration data gathered from 
Datix reports and the patient journey (case study) and was reviewed by the project team. 
The questions for the questionnaire were first drafted by the investigator and input from the 
transplant pharmacist and academic supervisor was then given. The questions asked were 
focused around where in the process of prescribing and administering of immuno-
suppressants, things were likely to go wrong. The administration part focused on nurse 
administration and self administration with focus on patient education and knowledge about 
their immuno-suppressants. Lastly in the administration part, a few questions were included 
regarding patient adherence to drug regimen (compliance) and how staff perceived this. It also 
focused on the GPs role in a transplant patients‟ drug therapy and how GPs were involved in a 
transplant patients‟ use of immuno-suppressants. This was to see whether the GPs 
involvement could be a potential high risk area for example in the case of drug interactions as 
a potential issue. The same questions were asked to all staff  including junior to senior grade 
nurses and doctors from both renal and liver transplant wards except question two regarding 
prescribing:  
Question 2: Monitoring is important in the use of immuno-suppressants, and blood tests are 
taken frequently. How are the results of the blood tests taken into consideration at the time of 
prescribing? 
This was left out for nurses as it regarded the specifics of monitoring and prescribing and was 
not considered within their area of expertise to answer. Staff were invited to participate via 
the transplant ward liver pharmacist and follow up communication (appendix) to arrange an 
interview time and place was undertaken by the investigator who attached a copy of the 
protocol for information. A convenience sample of a range of staff were selected; four doctors 
and one nurse. All replied and would participate except for one doctor who never replied. The 
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charge nurse then provided the investigator with two nurses willing to participate in 
interviews; one junior and one senior grade nurse. The doctors that replied were booked in for 
interviews and the investigator met with them in their offices. The renal transplant pharmacist 
organised two more doctors for interviews; one junior and one middle grade doctor. The liver 
transplant ward pharmacist arranged for one additional junior doctor to be included. All the 
interviews were recorded and all staff participating were made aware of this at the start of 
each interview. They were also informed that the tapes would remain anonymous and would 
be destroyed following transcription. The recordings were transcribed. 
The pharmacists on the transplant ward were also asked to list the care issues they encounter 
most frequently (appendix 7). 
3.3 Prospective surveys; pharmacist check-list 
The intention was to further characterise the assessment by using data from prospective 
surveys. The investigator adapted a checklist based on the categorising of common causes of 
drug  therapy problems done by a previous master student[35].  The adaption was made by the 
investigator and transplant pharmacist by carefully selecting which points to include in the 
checklist based on relevance to the topic of this study. The check list was also made as user 
friendly as possible to encourage completion. This would also rule out potential mistakes that 
could be encountered based on too much text and the check list being too complex. The two 
pharmacists on the transplant ward were to tick the appropriate boxes in the checklist. The 




Although the intention was to collate all the information retrieved from other data collection 
and conduct an FMEA to be able to agree the processes and score the levels of risk at each 
stage in the process, time did not allow this part of the study to be undertaken.  
4 Results 
4.1 Patient journey 
The case study (appendix 9) allowed the investigator to map the process of a transplant 
patient‟s journey. The staff involved at each step and communication between staff and with 
the patient was also clarified. The process regarding self administration and patient education 
were highlighted. See patient journey in appendix for more details. 
4.2 Data collection 
4.2.1 Datix® 
When reports are written on Datix the staff who report, put in their ID and location. The Datix 
incident form that staff fill out is quite extensive and what has to be filled out depends on 
what the reporter actually fills in as they go along. In the printed report the following columns 
come up; ID, Location, description, action taken, lesson learned, drug name, grade and 
opened date. This is only part of what the reporter fills out however. A hypothetical example 
































Table 2: Datix reports from the transplant ward 
Total number of reports ward 206 (transplant) for 2010 34 
Number of reports lacking specifications for specific drug in the column 
drug name * 
8 
Number of reports regarding immuno-suppressants** 9 
Number of reports regarding medication schemes in general***  5 
Number of reports on immuno-suppressant regarding missed doses 5 
Number of reports regarding immuno-suppressants graded as low 6 
Number of reports regarding immuno-suppressants or medication schemes 
in general graded as medium 
Number of reports regarding tacrolimus 






*Not all reports are regarding immuno-suppressants. One report has tacrolimus in the 
description column and is regarded as a report on immuno-suppressant. 
**Including only those reports with specific names of immuno-suppressants. Some reports 
did not include any drug names. 
*** These did not have any specific immuno-suppressant drugs mentioned 
The reports were dealt with in terms of reports containing specific medication names, reports 
not concerning medications (one report was as an example regarding fluid charts) and reports 
regarding medication schemes in general where the staff filling out the report often put 
multiple in the drug name column. There were eight reports on immuno-suppressants where 
the drug name was mentioned in the drug name column. In addition there was one report 
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missing drug name but that had tacrolimus written in the description column. This was then 
regarded as one of the reports on immuno-suppressants. The reports regarding medication 
schemes in general often concerned all or some of the drugs the patient was on, multiple 
medication doses missed, multiple medication errors in kardex, wrong information given to 
patient about multiple drugs etc. These were likely to include one or more of immuno-
suppressants but that could not be proved as no drug names were listed in these instances. 
There were five reports regarding medication schemes in general. The nine reports regarding 
immuno-suppressants and the five reports on medication schemes in general were considered 
focus points in this project. All together these fourteen reports were reviewed in depth. The 
remaining 20 were read through but not considered relevant for this project. 
Six of the reports were on tacrolimus. Of the remaining three reports on immuno-
suppressants, there was one on azathioprine and two on MMF. Of the fourteen reports 
reviewed in depth, seven of the reports were regarding missed doses. The remaining reports 
were on multiple medication errors in drug kardex,  expired azathioprine found in patients 
locker, tacrolimus not prescribed, wrong tacrolimus strength given, medication not signed for, 





Table 3: Summary of data from Datix reports regarding immuno-suppressants 
Drug name Description Lesson learned Grade 
Tacrolimus At the morning renal ward 
round it was noticed that 
the patient had not 
received her prescribed 
22.00 anti rejection 
medication (tacrolimus). 
Patient did state that the 
medication had been 
withheld. 
Medical staff did not prescribe 
that patient‟s medication not 
state that it was to be withheld 
or pass this information onto 
nursing staff. Nursing staff did 
not check with medical staff 
but assumed drug was to be 
withheld, which it was to be on 
this occasion 
low 
Tacrolimus Patient founds not to have 
taken tacrolimus dose. 
Patient stated he was 
given the tablets but fell 
asleep and forgot about 
them. 











Tacrolimus-prograf Query wrong dose of 
tacrolimus-prograf given 
at morning meds, day staff 
(bank nurse) signed for 
22.00 prograf dose rather 
than 10.00. Doses 
different. Query whether 
patient got 1 mg rather 
than 0,5 mg at 10.00. 
Incorrectly read drug chart low 
Myfortic On reviewing the drug 
kardex I noticed that the 
previous evenings dose of 
myfortic had not been 
signed for 
Lesson learned missing  
Mycophenolate mofetil On checking the drug 
kardex it was noticed that 
mycophenolate mofetil 
dose for 20.00 the 
previous day had not been 
signed for. 
Drug prescribed at handover 
time and not at time when 









Tacrolimus Patient prescribed 13 mg 
Advagraf at 10 am and 
was given 13 mg Prograf 
in error 
Incorrect drug administration. 
Bank nurse unaware of two 
different preparations of 
tacrolimus. Drug prescription 
incorrect, prescribed as 
Tacrolimus rather than 
Advagraf (However advagraf 
stated in column) 
low 
Azathioprine (AZA) Expired  AZA 50 tablets 
found it patients locker 
Nursing staff not following 
drug administration policy 
low 
Tacrolimus 10 pm tacrolimus not 
prescribed a transplant 
patient 
Medical staff not prescribed 
routine medications as required 
daily 
low 
Tacrolimus Tacrolimus sent down to 
haemodialysis room 1 
with patient, in order to 
take at 10 am 
Lesson learned missing low 
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4.2.2 Staff Interviews 
Some of the high risk areas in prescribing and administration identified by staff are listed 
below. 
Table 4: High risk areas in prescribing 
High risk areas in prescribing  
Not using a suitable kardex i.e. one that has a table for 
immuno-suppressants on the back 
Generic names not used when prescribing  
Blood tests assumed to be 12 h troughs when this is not 
always the case. 
Lab tests: getting the bloods to the lab on time 
Lab tests: the labs to process it in time 
Doctors prescribing the medications in time 
Unclear hand writing 
Interactions; Prescribing interacting drugs or not noticing 
when interactions are present. 
Reducing immuno-suppression appropriately 
Incorrect monitoring  
Failure to adjust according to  monitoring 
Staff on rotation might be relatively inexperienced 







Table 5: High risk areas in administration 
High risk areas in administration 
Generics; not knowing about different formulations 
Patient not eating, drinking or vomiting  
Patient unable to take the drug orally 
Nurses being busy, getting caught up etc 
Patient relying on family too much 
 
Formulation, timing of dosing and strength of preparation 
Nurses being busy might lead to more errors in terms of switch between drugs and different 
formulations. Staff were in general very supportive and understanding towards the nurses and 
their busy schedule. Timing of doses was mentioned as a source of error as it was identified 
that deviation from set times was bound to occur. 
“..when everyone have something prescribed at 10 am and 10 pm, it is impossible for nurses 
to give everyone their drugs at exactly 10”-junior staff member 
Another issue raised was nurses feeling like they were taking over too much of the 
responsibility for the drugs themselves and that they did not always feel they had the skills for 
it. One senior nurse mentioned that they had lack of time to sit and educate the patient they 
way they deserved to be educated and that it would be better for pharmacy to do this part of 
the patient education. 
One comment was made by a doctor who said that it was important for patients to take on 






All staff considered drug interactions to be important. It was commented that patients might 
receive interacting drugs when absent from the transplant ward or in the community setting 
and that this could disrupt their blood levels of immuno-suppressants. It was however 
emphasised by one senior staff member that if they got a patient that was on a regular dose of 
an interacting drug, then a dose adjustment might be all that was needed. It was considered a 
safe and constant interaction and it would not stop the doctor from prescribing either one of 
the drugs, but it would be taken into consideration at the time of prescribing the initial dose. 
In the unit, it was agreed that interactions were taken into consideration. However one staff 
member stated that this might not always be the case for GPs. It was also mentioned that 
occasional ones might be missed but the important ones were always considered. One senior 
nurse commented that the nurses were considered experienced and might also pick up on 
interactions because they deal with the drugs every day. 
One junior nurse mentioned an interesting comment on interactions with food as well and said 
the reason for prescribing (tacrolimus) at 10 o‟clock was so the medications would not 
interact with each other or food. 
“I think they‟re taken into consideration. They might not always be known. From the GPs 
point of view, they are reasonable good at calling us if they have a concern or if they‟re 
starting new meds. It‟s quite regular for them to phone and ask “is it ok if we give this?”, but 
we‟ve been called out a few times particularly with antibiotics like clarithromycin or 
something like that where that hasn‟t been discussed with us and they‟ve been put on it. Not 
just by GPs but by other hospitals. So I think within the unit we‟re reasonable good, but as a 




All staff agreed that adherence to drug regimen was very important in this group of patients. 
However when asked whether they thought patients did adhere to drug regiments, the 
responses were variable. Some stated it was variable and others that they thought most 
patients did adhere. 
Interestingly one senior staff member said: 
“It depends on how you define adherence. If you mean adherence 90 % of the time they take 
their tablets around 1 hour around when they‟re suppose to, I‟d say yes. If your adherence is 
strict I‟d say no.”-senior staff member 
Another senior staff member said on the whole patients were compliant especially in the early 
days, but that there were patients that with time started to get less compliant and it tended to 
be the ones that did not attend clinic. These patients were considered a worry as they might 
lose their graft.  
When asked why they thought patients might not comply various answers were given. Issues 
such as patients being worried about side effects, poly-pharmacy leading to confusion and 
lack of understanding of drugs were listed as potential reasons for non-compliance.  
Patient psychology was considered an important issue in compliance. A mix of forgetfulness, 
impact upon their lifestyle, social factors, stigma attached and genuine mistakes were 
mentioned. 
“I‟d say the ones that do and the ones that don‟t it‟ll be a mixture of forgetfulness and chaotic 
lifestyle. Other patients are young so I suspect there‟s a lot of social factors behind why some 
people don‟t take their immuno-suppression”-junior staff member 
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Another issue with patients not being compliant was that with the CNI‟s the dose changed so 
frequently that it was important that the information kept up with the patient or it could be a 
potential problem. Another concern with this was that the patient might not have the right 
tablets for the doses change, so they might need to go to GP and then to community pharmacy 
who might not have it in stock. This might lead to the patient getting delayed and not 
changing the dose when they should. 
Patient education and documentation 
When staff were asked if patients went home with enough knowledge to take their immuno-
suppressants the way they were intended, patient individuality was highlighted as an 
important issue. Patient being different in age, culture, co-morbidities and perception of their 
conditions meant that they should receive education tailored to their needs. 
“I think it‟s important that they have lots of different sources of information so that as well of 
verbal communication, they need written communication.”-Senior staff member 
It was also acknowledged that lack of information could result in patients not taking 
medication at the right time, with interacting medications or not taking their medication at all. 
This could ultimately end in graft loss. 
Staff were on the whole informed and aware of the education the patients received. They 
mentioned transplant co-ordinators, nurses, pharmacists, staff nurses, and doctors as the 
people who educated the patients. The most frequently mentioned were the nurses and 
pharmacists. One junior doctor did state that most of the education came from pharmacists 
and that the doctors did not give much education to patients about safely taking immuno-
suppressants. However one pharmacist did mention that they might not speak to the patient if 
the patient was being discharged at a weekend or evening. 
47 
 
One junior doctor did not feel that doctors participated enough in giving patient‟s information: 
“We probably don‟t tell them anything at all really other than what dose to take so from my 
point of view we don‟t give them enough information.”-junior doctor 
Regarding documentation of education, the nurse‟s notes on self medication were mentioned 
as a form for documentation. It was thought by one member of staff that pharmacists “wrote 
something in their notes”. One senior staff member said that documentation was probably 
variable. Another senior staff member expressed worries that it might not be documented: 
“There‟s a formal self medication programme which is documented. I have some concerns 
that it is not (...) We see patients who have passed through the self med programme, and come 
and clearly don‟t understand and I think that comes back to what I was saying with individual 
patients‟ need to be treated in different ways but the education continues and we reiterate a lot 
of the purpose and function and reasons behind the immuno-suppressants when they come to 
the clinic and that‟s not formally documented but it happens.”-senior doctor 
Most staff knew that there was written information given to patients. They mentioned the 
green book patients get at discharge, nurses handing out information sheets when introducing 
self medication. These sheets from the nurses had to be read by the patient before self 
medication started and could also be given to relatives. The discharge script was also 
mentioned as written information. However, some staff members showed uncertainty about 








Staff agreed it was very important that the GP was informed about what happened in clinic 
and hospital; 
“Very important, because in effect they‟re the ones doing the prescribing. That is also a 
source of problem; having to convey information to the GP, and that prescription then has to 
go to pharmacy and pharmacy then have to dispense the medication and each of those steps 
induces delay and potential error.”-senior staff member 
However staff did recognise that there were multiple issues involved in this. One senior 
doctor stated one of the major issues they had encountered the recent months and years was 
correspondence with GP because there were concerns around getting clinic letters out in time 
and they often ended up lagging behind. The GP could then end up receiving different letters 
at the same time with different doses as there are frequent dose changes in the use of immuno-
suppressant to transplant patients. Another problem was if the patient went for repeat 
prescriptions as the dose might be wrong because it might not be up to date. It could be even 
worse if there was a change in which drug the patient was on because the patient might not be 
aware that there had been a change at all. One senior doctor recognised that they as doctors 
could be better at this and made the suggestion that perhaps if the patient always had their 
green book with them at it was signed by doctors this might make it clearer. 
With regard to the perceptions of consequences about the GP not being informed, staff saw 
the biggest issue as the fact that patient could receive inappropriate immuno-suppression in 
the form of too little or too much immuno-suppressants, this again could lead to graft loss. A 
senior staff member mentioned that he/she had not seen any major consequences and that it 
was more a matter of time wasting for the GP who had to chase transplant doctors around. 
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Also mentioned was that patients might find it frustrating; they‟d go to the GP and GPs might 
not be happy to prescribe the drugs so they could often end up coming back to the unit and 
asking for a hospital prescription. One senior staff member said what would help was if the 
clinic letters were sent quickly but that it could be several days before a letter was prepared 
and sent due to lack of secretarial staff. Also he/she said that it would help if the patient was 
well informed and they had access to a range of tablets and sizes so they could do dose 
adjustments without having to go through GP. The patient having to wait to go to GP was 
considered problematic and was not considered a good option. 
It was agreed that the GP should have an updated list of medications the patient was on, 
exactly what drug they were on and the preparation of what drug they were on. Also 
mentioned by a junior staff member was that they should get an education pack about 
tacrolimus, the importance of it and the risk factors with it. Staff also thought the GPs should 
have access to shared care protocols and that they would get information from there. In 
addition GPs should be informed about what plans the doctors had for changing the immuno-
suppressants and what was expected from the GPs. 
“Transplant is fairly specialised and I don‟t think the GP will want to know particularly why 
we‟ve changed doses etc. I just think they need to know the prescription and the dose. I think 
if there‟s a switch in medication, there needs to be some explanation to why the switch has 
taken place as well as the dose that is used, whether that dose will change in time of whether 
it‟s a fixed dose forever. So I think they‟d like to know if it‟s likely to change and over what 
sort of time period.”-senior staff member. 
On the question of what information is provided to GP most staff mentioned the discharge 
letter. This had details of the hospital stay and what drugs the patient was on. Also the follow-
up would be included in this letter. The green book that patients receive when doing self 
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medication was also mentioned. Some staff members did not know many details about the 
information given to the GP. 
“…I‟m not sure of what everybody‟s practice is in terms of saying that a lot of drugs are 
going to be stopped at 3 months and altered. I usually say that at 3 months there will be 
significant changes (…) I‟m not sure if there is any other formal information that is given to 
GP.”-senior staff member 
Teamwork 
When asking the staff members about who they thought doctors would contact if they were 
uncertain about anything regarding the prescribing of the drug, the action taken depended on 
the grade of doctor. Most junior doctors would ask their seniors or the pharmacist. One junior 
staff member assumed that senior doctors made their own decisions. It was also stated that in 
the renal unit they might look it up in the renal unit handbook (known as EdRen) as well as 
ask a more experienced doctor. Staff were in general very supportive of teamwork. They 
valued their seniors‟ opinions as well as other professions‟ competence and knowledge. 
The pharmacists were valued and both nurses and doctors stated that they frequently asked the 
pharmacist for advice: 
“Speak to the pharmacist! We do that quite regularly. We certainly value the pharmacists and 
they‟re quite rigorous at looking at things up so if we‟re uncertain I usually just speak to the 
pharmacist.” 
Staff also looked things up and asked their seniors for advice: 
“I suppose depending on the time of day and the need to find the answer, the BNF is 
available. If not; one of the transplant pharmacists (...) If it‟s a middle grade doctor; then one 
of the senior transplant clinicians.” 
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Pharmacy in general was also considered a place to seek information and advice: 
“Our pharmacist is very much involved with the ward rounds and is on the ward every day 
and they all know the pharmacist which I‟m amazed at which is fantastic. So the pharmacist is 
our first resource as well as the senior doctors as well... And there‟s always the out of hours 
pharmacy if you every need advice, or anyone else in the other end of the phone which would 





 4.3 Pharmacist check-list results 
   
1 2 3 4 5 6 7 8 9 10 
Initials                       
Ward:    206 206 115 206 206           
type of transplant   Liver Kidney Kidney Kidney+pancreas Kidney           
Number of days since transplant:   14 1 0 1,5 yrs             
Pharmacist:                        
1 Unnecessary drug therapy 
 a) There is no valid medical indication for the 
drug therapy at this time                     
  
b) Multiple drug products are being used for a 
condition that requires fewer drug therapies                     
  
c) Drug therapy is being taken to treat an 
avoidable adverse reaction associated with 
another medication                     
  d) The duration of therapy is too long                     
                        
                        
                        
2 Need for additional drug therapy 
a) A medical condition requires the initiation of 
drug therapy 
  
                
  
b) Preventive drug therapy is required to reduce 
the risk of developing a new condition                     
  
c) A medical condition requires additional 
pharmacotherapy to attain synergistic or additive 
effects                     
  
d) The duration of drug therapy is too short to 
produce the desired response                     
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3 Ineffective drug 
a) The drug is not the most effective for the 
medical problem                     
  b) The formulation of the drug is inappropriate                     
  
c) The drug is not effective for the indication 
being treated                     
  d) The dosing interval is incorrect                     
  f) Route of administration is incorrect                     
                        
4 Dosage too low 
a) The dose is too low to produce the desired 
response       
  
          
  
b) The dosage interval is too infrequent to 
produce the desired response                     
  
c) A drug-drug/food/lab/disease interaction 
reduces the amount of active drug available                     
                        
5 Adverse drug reaction 
a) The drug product causes an undesirable 
reaction that is not dose-related     
 
              
  
b) A safer drug product is required due to risk 
factors                     
  
c) A pharmacodynamic drug-
drug/food/lab/disease interaction causes an 
undesirable reaction                     
  d) The dosage regimen was changed too rapidly                     
  e) The drug product causes an allergic reaction     
 
              
  f) The drug product is contraindicated                     
                        
6 Dosage too high a) Dose is too high                     




c) A drug-drug/food/lab/disease interaction 
occurs resulting in a toxic reaction to the drug 
product                     
  
d) The dose of the drug was administered too 
rapidly                     
                        
                        
                        
7 Inappropriate compliance a) The patient prefers not to take the medication                     
  b) The patient forgets to take the medication                     
  
c) The patient cannot swallow or self-administer 
the drug product appropriately                     
  
d) The time of dosing or the dosing interval is 
decreasing compliance.                     
                        
8 Unclassified i.e. Non-DTP a) Formulary adherence, e.g. generic switch                     
 
In the liver transplant ward and renal/pancreas transplant ward there were six reports all together five of which were in the kidney transplant 




5.1 Patient journey 
The patient journey allowed the investigator to be able to map the transplant patient‟s journey. 
It allowed the investigator to look at a real patient‟s experiences, co-morbidities, medications 
and complications in retrospect whilst at the same time looking at guidelines and protocols to 
see if there were any areas for improvement to minimise risk of harm to the patient. The 
patient journey also worked as a background so the investigator could get familiar with the 
journey of a transplant patient through the healthcare system and how the different 
professions were working together to optimise care for this group of patients. The investigator 
read protocols and guidelines and attended clinic visits, assessment meetings and ward rounds 
in addition, to help give a clear picture of how things worked in practice. This allowed the 
investigator to see how theory was put into practice. The multidisciplinary teamwork was 
made very clear when attending the ward rounds and the assessment meetings as a range of 
different professions were allowed to express their opinions. The discussion then took into 
account every profession‟s view of each patient. On the ward round meetings the pharmacist‟s 
role was emphasised as other professions (mostly doctors) often asked the pharmacist for 
advice on medications. When spending time on the ward however, it was also clear that 
nurses found it easy to ask the pharmacist for advice. 
When observing the clinic visits (the investigator only attended clinic visits with senior 
doctors present) it was clear that the doctors were certain of the common concerns around the 
use of immuno-suppressants. Questions were asked about side effects and all the medications 
were always gone through with the patients to ensure they were up to date on every 
medication. For the liver transplant ward‟s out-patient protocol[19] there exists a memory aid 
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(one A4 sheet) that can be used in clinic visits. The investigator only attended one clinic visit 
on the liver transplant ward so it is unknown if this memory aid is often used. There is a 
potential risk here if decision making is intuitive rather that analytical. The experienced 
doctors might not feel the need to use the memory aid. However  an article written on errors 
in clinical reasoning states that being older and a more experienced doctor does not guarantee 
better quality of care or lower risk of reasoning errors[36].  The article also states: 
“Irrespective of whether diagnosis or management is the focus, or whether analytical or non-
analytical reasoning modes predominate, all decision making is vulnerable to different forms 
of cognitive and affective (emotional) bias or error.”[36] 
This emphasises that there is risk associated with all decision making. However there are 
ways to minimise these risks for example by every doctor attending clinic always using the 
memory aid. Therefore it would be of further interest to know if all staff attending clinic visits 
are aware of the memory aid and if they do use it on a regular basis. It would also be 
interesting to know how often it has been reviewed and updated. 
5.2 Characterising harm assessment 
5.2.1Datix® 
The investigator observed when one pharmacist reported on Datix and it was clear that 
reporting demanded the full attention of the reporter and sufficient time to report so that all 
information needed would be included in the report. Staff are suppose to get education on 
Datix when starting a job, however there might be room for improvement in the education on 
how to use Datix, why to use it, it‟s value and when to report incidents or near misses. There 
is a lack of standard definitions around what needs to be reported and how the reports are 
graded and used to improve patient safety. For example one report regarding a missed dose of 
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immuno-suppressant was graded as medium whilst another regarding an immuno-suppressant 
that had not been prescribed at all, was graded as low. It might just be that the incident was 
regarded as low because the likelihood of the pharmacist identifying the error was considered 
high and so the patient would not come to any harm, however one cannot know this from 
reading the report alone. This shows how there is a lack of standards for the people 
investigating the incidents. There needs to be standard definitions of what is considered low, 
medium and high. All in all, training and information on better use of Datix is needed. 
Of the reports reviewed in-depth half of them were regarding missed doses. The missed doses 
had various reasons for happening; nurse not signed for medication, nurse not given 
medication, patient fallen asleep, misunderstandings and miscommunications between staff 
and patient were common explanations. Nurses have a lot to do around the ward and are busy. 
When medication at times is prescribed at administration times not “normal” to nurses it can 
be forgotten. The transplant ward has implemented a new procedure to reduce drug errors in 
administration. The nurse on medicine rounds wears a red vest that says: 
“Do not disturb. Nurse on drug round” 
This lets the nurses focus fully on what drugs they give each patient and allows them to work 
without interruption. It would be of further interest to see whether these vests do prevent 
errors from happening. 
One weakness of Datix is that it is subjective in that staff express their own opinion of what 
happened whilst there might be more than one side to the story. Investigation is however done 
following the reports. The most important weakness may be the known underreporting going 
on, which means that the incidents that are reported, might not be representative for what is 
actually happening. There is a lack of standards for what should be reported on Datix. This 
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means that staff have different opinions on what should be reported, resulting in subjective 
viewpoints influencing when staff report incident and when they don‟t. For example one staff 
member might only report what he/she considered to be serious incidents, whilst others only 
report what they consider to be minor incidents. There might also be disagreement about what 
is considered serious. Furthermore it might vary between different professions what they 
perceive as serious incidents. Moreover it might just be that reports are reported when 
convenient to staff. Reports lacking important details are another concern; for example one 
report did only have the description and action taken-columns filled out. It was not clear what 
the problem was or how they handled it. These reports are not complete and have very limited 
value for using Datix for identifying areas of improvement in a project such as this.  
When presenting this project for staff, it quickly became clear how members of staff are not 
afraid to admit they do not report on Datix. This can be for several reasons. For example staff 
might not see the benefit of reporting on Datix or they simply don‟t have time. There is a need 
for motivation and understanding of purpose if the goal is for everything to be reported on 
Datix. If everything was reported it would increase the workload for the person in charge of 
going through reports and there might be need for more staff time to go towards it. If this was 
to happen there would need to be a clear message as to why it was so important to report 
incidents or near-misses on Datix. This might also call for increased funding.  
The fear of blame would be one matter that would need to be eradicated in order for the focus 
to be on learning from incidents and not blaming individuals for it. This would involve 
changing staff‟s perceptions and attitude towards voluntary reporting which in itself is a 
challenge. When presenting the topic of this project for them, staff themselves recognised the 
need for actual data and numbers to back up and assess quality of patient care. At the 
development and discussion of this project it was clear that there was a huge gap in 
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knowledge about whether transplant was an area for improvement that needed attention or 
not, namely because Datix as the one measure for collecting data on incidents was not being 
used adequately. 
5.2.2 Clinical staff interviews 
The staff interviews highlighted many high risk areas in administration and prescribing. 
However the weaknesses to the interviews were that some of the questions asked were long 
and might have been misinterpreted or misunderstood. The selection of staff was another 
issue. There were only two nurses whilst there were six doctors. This might have made the 
interview results biased towards the doctors‟ opinions and perceptions. If time had allowed it, 
the investigator could have included staff to the point of saturation. The staff included 
consisted of a convenience sample however, the results obtained might not have varied very 
much even if more were included. If more doctors/nurses were included the investigator 
considers it likely that they would have mentioned many of the same high risk areas that had 
already been identified. Amongst the senior doctors, there might have been bias introduced as 
the ones likely to attend and say yes to participate were chosen. This might also have been the 
ones who were good at following procedures and were confident. This might mean that the 
sample of people chosen were not representative of all staff in the transplant wards. However 
it can be considered a strength to this study that doctors who were confident and not afraid to 
air their opinion were included as they were not afraid to identify weaknesses in the process 
of prescribing and administration of immuno-suppressants. Not including these doctors, could 
have lead to fewer high risk areas being identified. 
Issues regarding different formulations, timing of dosing and drug interactions 
Nurses being busy and having many areas of responsibility was considered an area where 
errors could occur. Non-nursing staff expressed an appreciation of understanding for this. 
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Patient taking on responsibility themselves for their medication was considered important in 
this context. Patients understanding their medications, recognising packages, tablets, 
formulations etc might help to minimise the risk of administration errors happening. However 
many patients rely fully on nursing and medical staff, so they might not question them even if 
they were unsure. One nurse highlighted an important point; the feeling that the nurses were 
taking over too much of the responsibility for the medications and that did not always have 
the skills for it. This shows that there might be an area for improvement in terms of increasing 
the amount and type of education the nurses receive about medications so that they can be 
confident in administering medications as well as educating patients on them. More pharmacy 
involvement was suggested in terms of patient education, so that nurses did less educating 
because the nurses did not always have the time to sit with the patients and educate them. On 
the other hand the pharmacists do already play an important part in educating the patients on 
the transplant ward. Pharmacists are however not on the ward at all times, and if patients are 
discharged on weekends and evenings, they might not be able to meet a pharmacist and so 
nurses have to do the education. If nurses are not used to this, or don‟t feel confident in doing 
it, then it might be that not all patients receive the education they should. More detailed 
documentation of education could help identify whether some patients don‟t get the education 
they should. 
Drug interactions were considered important in the administration and prescribing of 
immuno-suppressants. It was however emphasised by staff that the risk here lied mostly in the 
community setting. The transplant ward was considered safe in terms of having pharmacists 
to pick up on interactions as well as clinical staff who were specialised and therefore more 
aware of many of the common interactions with immuno-suppressants. The GPs prescribing 
interacting drugs and community pharmacy not being aware of the patients‟ immuno-
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suppressant drugs might lead to community pharmacy dispensing interacting drugs. It was 
however also stated by a senior doctor that GPs were good at phoning the transplant ward 
when introducing new medications. The interacting agents most frequently mentioned were 
antibiotics.  
The interactions and communication with GP and community pharmacy is something the 
investigator would consider important for future investigation. The next step might have been 
to include the GPs and community pharmacies and put measures in place to see if it improved 
patient care. It would be of interest to see if drug interactions and communication between 
community and hospital is a high risk area because it could be prevented by educating and 
informing staff about patients‟ medications. Also the liver in and out-patient protocols 
(appendix 9 and 10) are not possible to access online. The protocols have detailed information 
about interactions and it could be of benefit to put it online so GP and community pharmacy 
could access it. This would also ensure that the most up to date version was always available. 
In addition if patients or GP lose their copy etc, they could access it online. However the 
disadvantage to this might be that the protocols contain a lot of irrelevant information. The 
best option might be to update the shared care protocol to include more details or to simply 
take out relevant information for GPs from the protocols and make it into an information sheet 
for the GPs. 
Compliance 
There were several different opinions on whether patients were considered compliant or not. 
There were many thought reasons for non-compliance. Patient‟s fear of side effects was one 
issue. This could be prevented with education and information. Age and forgetfulness 
amongst patients was another. This could be helped by educating relatives so they could 
support patients and clear written information to patients in the form of reminders. Also, dose 
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changing so frequently that patients don‟t have the right strength at the time of dose change 
was an issue. Patients might then have to wait for GP to prescribe and then wait for 
community pharmacy to dispense. This might lead to remarkable delays and ultimately 
unintended non-compliance by the patient. One suggestion was made that patients should 
always have a range of tablets and tablets sizes, however, the cost of immuno-suppressants 
are high and this solution might lead to much wastage and higher costs. One staff member 
mentioned giving the patients a range of tablets of different strengths. However this could 
potentially confuse patients and do more harm than good if they end up taking the wrong 
strengths of tablets. Another important point was that patients were thought to get less 
compliant as time went by. Here, addressing non-adherence as time went by might be key. 
Educating patients every so often so they understand that the risk of graft loss remains as time 
goes by and compliance is always important. This might be best done in the clinic where 
patients come for check-up and doctors could emphasise the risks of non-compliance. 
However one senior doctor did state that they did emphasise the importance of immuno-
suppressants in clinic: 
”(...) we reiterate a lot of the purpose, function and reasons behind the immuno-suppressants 
when they come to the clinic and that‟s not formally documented but it happens.” Senior 
doctor 
The problem still remaining is that the patients who are non-compliant in their medications 
might also be the patients that don‟t attend all their clinic visits. Future work in this would be 
to assess the patient‟s perceptions of the education they get, their thoughts around the 
importance of adherence to immuno-suppressants, their fears about side effects, their illness 
etc and from this see whether there is an area for improvement here. Also as one senior doctor 
pointed out, there would need to be a definition to adherence and what good adherence was 
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considered to be. This might very well vary between doctors, nurses, pharmacists and 
patients. 
Patient education and documentation 
There was a large variety in the amount of knowledge the different staff member had on the 
topic of education. Some knew very little about what education was being given, by who and 
how it was given. Others were fully aware of the self medication programme with the 
involvement of the pharmacy and nurses. It was clear that staff in this context did not have 
knowledge of what other professions roles in the education of patients was. Nurses and 
pharmacists had sufficient understanding of who was doing the education however there was 
still the issue that one nurse felt that nurses might be taking over too much of the educating. 
Most doctors knew about the education patients get, however they were on the whole unaware 
of the details regarding self administration and the documentation of this. One doctor also 
mentioned that the doctors were not involved in the education and recognised the lack of 
information patients got from doctors. However the investigator did attend clinic visits and 
did observe doctors in the clinic setting educating patients about their immuno-suppressants. 
One senior staff member stated that it was important for patients to have both written and oral 
information. The patients do receive both written and oral education through the self 
medication information sheets and through education from pharmacists and nurses.  
Regarding the documentation of self medication, nurse‟s notes were mentioned as a type of 
documentation. Several staff members did however state uncertainty about whether it was 
being documented and the quality of documentation. Nurses and pharmacists documenting the 
education they give might help clarify what impact this education is having and whether it can 
be improved upon or not. It would be of further interest to see what type of education is given 
and by whom. When asked about the written information given to patients, some staff were 
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unsure whether there was written information given and if so, what type. Most frequently 
mentioned was the discharge letter that the patients get. This again emphasises that not all 
staff knew what the other people on the ward were doing. Not knowing the roles of other staff 
might lead to some staff thinking that one thing is being done when in fact it is not happening. 
Further work could be done on the quality of the education given and written information 
given to patients, a patient‟s satisfaction survey on the education they receive, their 
understanding of their immuno-suppressants, the quality of the documentation done and 
staff‟s perceptions of other profession‟s roles on the ward. 
Communication 
In regards to communication with GPs it was stated that the GPs should have access to shared 
care protocols and that they would get information from there. However how many GPs 
actually do access the shared care protocol online remains unknown. It would be of further 
interest to find this out. It was also said that GPs should be informed about the doctor‟s plans 
for changing the immuno-suppressants and what the unit expected in terms of involvement 
from the GP. However it is difficult for a doctor to inform about plans to change immuno-
suppressants as this is done based on a whole clinical picture and many things can influence 
it. There is no set time frame for when different immuno-suppressants are reduced in dosage 
or removed except for prednisolone. Although the GPs normally don‟t initiate or discontinue 
immuno-suppressants, this does makes it a challenge for the GP to keep up as there are no set 
procedures and times for when this will happen. 
The communication with GP was thought to be important, however lacking in detail. There is 
room for potential errors here. Many staff stated that the risk of interactions were higher in the 
community setting than on the transplant ward and that this was a risk. Involvement of 
community pharmacy was not frequently mentioned. More involvement and information to 
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community pharmacy might reduce risk of interactions happening in community setting as 
they might pick up on interactions with immuno-suppressants if they knew the patient was on 
it. Community pharmacy and GP could get a standard information pack about immuno-
suppressants and perhaps a copy of the green book. If the green book was always taken to 
appointments with GP, clinic and community pharmacy it would help minimise risks of errors 
as an up to date list of medications would always be provided. The patients should be 
encouraged to use one community pharmacy and this pharmacy could perhaps keep a copy of 
the green medication reminder book in the patient‟s file. This would ensure that the 
community pharmacy was always aware that the patient was on immuno-suppressants before 
dispensing any other potentially interacting medications. However the limitation to this would 
be ensuring all copies of the green book were up to date. 
Also clinic letters lagging behind due to lack of secretarial staff etc was a problem. This could 
be solved by more secretarial staff so as to get letters out quickly and minimise risk of GPs 
getting different letters at the same time. However this would be difficult initially after 
transplant as clinic visits are frequent several times a week, and it would prove a challenge to 
get all letters out straight away. Repeat prescriptions were another issue raised as patients 
might go in with repeat prescriptions and the strength or dose might be wrong. One solution 
mentioned above would be for patients to always carry the green medication reminder book 
and always keep it up to date. It could be signed by doctors when updated however sometimes 
the alterations to drug regimens are given via phone and patients would have to be reminded 
to make a note in the green book if this was to happen. 
The shared care protocol which is available online for GPs was not mentioned by doctors or 
nurses. This is however a tool that could minimise risk to patients and provide the necessary 
information to GPs. This should be considered an effective tool to prevent harm, but staff not 
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mentioning it might mean that not many people are aware of it. If they are unaware of it the 
chances are that they don‟t recommend GPs to access it. 
Future work on this could focus on GP satisfaction surveys in terms of information given and 
whether they do use the shared care protocol. 
Teamwork 
Teamwork is important at the transplant ward. The pharmacists were valued for their 
contribution. Senior staff were seen as a resource and a place to seek information when 
uncertainty was present. When staff were asked the question of who they thought a doctor 
would contact if he/she was uncertain about prescribing of a drug, many mentioned the 
pharmacist. Some said that the middle and junior grade doctors might look it up somewhere 
and also ask their seniors, and that the seniors would make decisions themselves. The 
investigator also attended assessment meetings where the teamwork became clear and the 
different professions opinions were clearly valued. 
5.3 Prospective surveys; pharmacist check-list 
The pharmacist check-list included few reports. The recognised issue with clinical 
pharmacists is how to document what they do without it taking up too much of their time. 
Pharmacists don‟t necessarily make interventions but they provide quality assurance checks, 
this would be difficult to document. One might argue that it is the pharmacist‟s jobs to make 
interventions and do checks and so asking them to document everything they do might be 
asking them to do something that would impact their workload significantly. The pharmacist‟s 
job is to capture harm before it happens. It‟s their job to intervene and prevent harm. Asking 
the pharmacist to document everything they do would take up a significant amount of their 
time; time that could be spent on the ward preventing further errors. If the pharmacist‟s were 
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to document everything, there would need to be an appropriate system in place for it; a system 
that was user friendly and that did not take too much of their time. If the pharmacists did have 
some form of document on what they did it might however be beneficial in showing how 
valuable pharmacists are in preventing potential errors and costs associated with this. 
Weaknesses of the check-list were that it might have been too extensive in spite of the fact 
that it was simplified prior to use. It required reading and time. The investigator did not go 
through the check-list before hand with the pharmacists and explanation beforehand might 
have made it easier for the pharmacists to follow. Also a reason for a low number of 
interventions recorded might be that the patient numbers in transplant are not that high. Renal 
transplants are more common than liver, and the few more interventions included here might 
be reflecting this. However on the whole, liver and pancreas transplants are not that common 
and so a better solution would have been to do the check-list over a larger time frame, for 
example a year. This project‟s time frame did not allow for that to happen. 
5.4 FMEA 
Although the FMEA could not be carried out due to lack of time, it was clear that there were 
many high risk areas that were identified through the interviews and the rest of the data 
collection. Staff were asked about risk and where in the process things were likely to go 
wrong and so many of the aims of the FMEA were still captured. There were areas identified 
that were high risk. As further work an FMEA could be done as a follow-up to this project to 
allow more specific opportunities for improvement to be agreed. The patient journey could be 
used to map the process and be the basis for an FMEA. 
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5.5 Strengths of this project 
The strengths of this project lay in the use of a variety of different methods to obtain data. The 
retrospective look at reports from Datix allowed for background information to be given to 
get an idea as to what types of incidents are happening. The one-to-one semi structured 
interviews included a range of different professions (nurses, doctors and pharmacists) with 
different grades of experience (senior, middle grade and junior) and allowed for a range of 
opinions and hence high risk areas to be identified. The pharmacist check-lists helped the 
investigator look into actual incidents in terms of what types of reports that came in, which 
drugs were reported on frequently, how many incidents were reported etc. The case study 
allowed the investigator get an insight into the patient journey to be able to map the process 
which was initially supposed to be used to map the process for an FMEA. 
6 Conclusion 
Areas identified by staff as areas for improvement were in education to patients, education of 
staff, communication with primary healthcare professions with regard to immuno-
suppressants, teamwork amongst the staff on the ward and documentation of interventions and 
education.  The patient journey identified many high risk areas including the following: 
nurses being busy, interrupted or not giving appropriate education. Patients being non-
compliant in medications and follow-up meetings, doctors not having clear handwriting, 
doctors not writing the formulation of immuno-suppressant clearly (or at all). 
Database analysis confirmed that Datix was not a well used reporting system and incidents 
were mainly in the immuno-suppressant administration category. The incidents reported 
emphasised the need to follow safe use of medicines policy. The study confirmed that Datix 
needed to be made more user friendly and less time consuming. There were lack of standards 
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around grading incidents and there were also unanswered questions around when staff should 
report and how to report. In addition there was a lack of incentive to report and education is 
needed to make staff aware of the benefits of reporting in order for everyone to be able to 
learn from mistakes made. 
Pharmaceutical care issues were not well documented and there were no consistent 
interventions to confirm particular high risk areas. This shed light on the issue that 
pharmacists rarely document their work. The pharmacist‟s job is to prevent errors and harm. 
Therefore it is difficult to demand that all pharmacists document every intervention they do, 
as this would mean less time was spent on the ward preventing errors. 
The richest data came from interviews and highlighted actions that could be used to reduce 
risk of harm from immuno-suppressive therapy. The data collected can be used to generate an 
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Appendix 3: The original check-list 
Taken from Kari Jansdotter Husabø‟s master thesis”Clinical audit of 
structured pharmaceutical care plans 





















































A study of the prescribing and 
administration of immunosuppressant 
medication in patients receiving liver, 
kidney and pancreas transplantation
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 Develop and validate a tool to allow the 
analysis of the patient journey and identify 
opportunities for quality improvement of 
immunosuppressant medication use
 
1. Identify points where there is potential for harm 
resulting from use of immunosuppressant 
medication
2. Identify and quantify these risks using 
retrospective incident reporting (i.e. Datix) and 
recorded pharmacist interventions
3. Expand the harm assessment using perceptions 
of clinical staff 
4. Further characterise the assessment using data 
from prospective survey(s)
5. Validate the FMEA tool by presentation of 





 An FMEA is a tool to evaluate a process 
systematically. It identifies where the process 
might fail and helps to assess the impact of 
these failures.
 Steps in the process
◦ Failure modes (What could go wrong?)
◦ Failure causes (Why would the failure happen?)
◦ Failure effects (What would be the consequences of 
each failure?)
 
1. Select a process to evaluate with FMEA
2. Recruit a multidisciplinary team
3. Have the team meet together to list all of the 
steps in the process
4. Have the team list failure modes and causes
5. For each failure mode, have the team assign a 
numeric value (known as the Risk Priority 
Number, or RPN) for likelihood of occurrence, 
likelihood of detection, and severity
6. Evaluate the results




1. Identify points where there is potential for 
harm by conducting a case study to 
illustrate the patient journey
2. Historical incident reports from Datix and 
recorded pharmacist interventions will be 
used to characterise the harm
3. Interviewing and/or talking to clinical staff 
to expand harm assessment
4. Gather an expert multidisciplinary team to 
validate the Failure Modes Effect Analysis 












































Staff’s answers to interview questions 
Participant 1; junior doctor 
Administration 
1. What do you think are high risk areas in the administration of immunosuppressant 
medication in transplant patients? (That is, are there any particular steps in the medicines 
administration process where you think things are likely to or could go wrong?) 
Suppose there‟s a couple of things...first of all transplant patients aren‟t always admitted to 
transplant wards so they tend to go to other wards to start with anyway before they‟re referred 
to us. When people aren‟t used to looking after immuno-suppressants they either prescribe it 
at the wrong time or they don‟t prescribe it at all or they don‟t to levels. Or they do levels but 
the levels are done at the wrong time, they‟re not trough values. I suppose another problem 
with the administration is when they use the wrong brand so the wrong preparation so they‟ll 
use advagraf instead of prograf or give advagraf twice daily. So I‟d say they are the quite 
common things that could go wrong. I suppose other times is to do with the problem in 
administration would be when the patient is either not eating or not drinking or vomiting and 
is unable to take it orally. 
2. The nurses have a lot of responsibility and are busy around the ward. What impact do you 
think this could have on drug administration to patients?  
Do you think procedures are always followed? 
I think we‟re generally very good. Remember everybody has got it prescribed at 10 o‟clock, 
ten in the morning at 10 at night and it‟s impossible for them to give it to everybody at 10 
o‟clock because there‟s lots of patients, but I think the really do try to spread it between 10 
and twenty passed. And I think immuno-suppression in this ward anyway is definitely 
prioritized to be given. So I think it‟s probably done all right. The other issue it the 
Mycophenolate and Tacrolimus have to be given at different times, two hours apart and that‟s 
not always done in other wards. 
3. After being discharged, do you think the patients go home with enough knowledge to 
safely take their immuno-suppressants in the way they were intended? 
I have no idea! I would think so. I would hope so because they are very carefully counseled at 
the clinic and they get sent home with a booklet and with information leaflets and information 
packs which they read and usually the nursing staff would insure that they‟re taking their 
tablets independently before they‟re discharged. So, I think a great effort is made to make sure 
that they know what they‟re taking and how to take it and certainly I think one of the 
prerequisite to getting a kidney transplant is being able minded enough to comply with the 
treatment post transplant so I‟d like to think that was done pretty well. 
What are the risks if patients are not educated? 
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They will either take too much which is quite renal toxic and they cause hyperkalemia so 
they‟ll either get renal failure or hyperkalemia which is dangerous or they‟ll take too little and 
end up with vascular rejection so those are the problems, yeah. 
Do you know who educates the patient and is there a record of this?  
The education is definitely done by the nurses. I suspect the pharmacist is involved as well. 
The doctors certainly aren‟t involved in educating the patient. I don‟t think I‟m qualified to 
educate patients on anything to be honest. I don‟t think or don‟t know if there is any formal 
documentation being done. 
4. How important do you think patient adherence to drug regimen is in this group of patients? 
It‟s absolutely paramount. It‟s an essential part of the long term success of a transplant graft. 
5. Do you think most transplant patients do adhere to their drug regimens? If not, why do 
you think that is? 
I think it‟s extremely variable. I‟d say most of them do. It‟s very difficult for me to tell. I‟d 
say the ones that do and the ones that don‟t it‟ll be a mixture of forgetfulness, chaotic 
lifestyle. Other patients are young so I suspect there‟s a lot of social factors behind why some 
people don‟t take their immuno-suppression. 
Prescribing 
1. What do you think the risks are in the prescribing of immuno-suppressants to transplant 
patients? 
Ehm, when you‟re prescribing on the kardex, first of all you need to use a kardex which has 
got a table on the back for the immuno-suppressants and they‟re not always available in other 
wards. They are always available in this ward. Second thing is when you‟re actually 
prescribing, you prescribe it by either prograf or advagraf, generic names. You can‟t write 
tacrolimus or else they get the wrong preparation. You need to write on the actual prescription 
dose as charted not a normal dose. Quite often when they come into a ward that wasn‟t the 
transplant ward they often seen the patient takes 400 mg of tacrolimus twice daily and they‟ll 
prescribe that at prograf 400 twice daily and that will be given when actually it should be 
written as "as charted" because the dose is variable depending on what their levels are, and 
diarrhea etc etc. 
2. Monitoring is important in the use of immuno-suppressants, and blood tests are taken 
frequently. How are the results of the blood tests taken into consideration at the time of 
prescribing? 
Well we routinely do levels Monday, Wednesday and Friday and every time a level is done, 
it‟s checked that afternoon and there‟s an alteration made to the drugs. Sometimes we slightly 
pre-empt that. If a patient is going on to something like fluconazole we‟ll pre-empt the level 
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and ignore the level, but half the dose of tacrolimus expecting that it will go up when the 
patient takes fluconazole. So I would say it‟s taken into account every time. 
3. Who (which grade of doctors) does most of the prescribing of immuno-suppressants on 
the ward? 
The registrar will do most of the prescribing but the levels will be looked at by a consultant 
every day that they are done. 
4. How important do you think it is that the GP is well informed about what happens in the 
clinic and hospital?  
I‟d say it‟s extremely important but it‟s such a specialist area, it would be very difficult for the 
GP, or anybody who is not working in transplant to be able to make good decisions about 
immuno-suppression. So it‟s very important that they‟re informed about what‟s going on at 
the same time any decisions that need to be made, should be done by the transplant team. 
What are your perceptions of consequences if the GP is not being informed? 
I‟ve not come across any consequences of GPs not being informed, yet. Probably because I 
work in the ward not in the out-patient clinics. So I do a lot of discharge for this group of 
patients but I‟ve not come across a disaster yet where GP hasn‟t been informed. 
5. In your opinion, what information needs to be provided to the GP? 
The fact that the patient is on it, exactly what drug they‟re on and preparation of what drug 
they‟re on. All the blood are done at the transplant clinics here pretty much rather than the GP 
so what investigations need to be done and when the patient is next going to be seen. 
6. What information is provided to the GP about current drug regimen at discharge, and 
eventual changes in drug regimen and how is this documented? 
The patient gets the formal discharge letter which I do and that details what‟s happened 
during the patients admission and what changes there are in the patients drugs. A full list of 
their current medication doses and usually what follow up has been arranged for them. So 
that‟s what formal documentation they will get. 
7. At the time of prescribing, do you think drug interactions are taken into consideration? 
Yes 
8. Would you consider drug interactions to be an important issue in the administration and 
prescribing of immuno-suppressants? 
Extremely. Occasionally it does happen when a patient that‟s not in the ward is given 
clarithromycin or fluconazole or something in the community and it‟s disrupts their immuno-
suppressant levels so I‟d say it‟s an absolutely essential. 
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9. If at a point in time, the prescribing doctor is uncertain about anything regarding 
prescribing of the drug, what action do you think the doctor will take? 
Depends on the grade of doctor. So I would phone my registrar or the pharmacist. My 
registrar would speak to his consultant or the pharmacist and the consultant would usually 
make their own decision. 
Participant 2: middle grade doctor 
Administration 
1. What do you think are high risk areas in the administration of immunosuppressant 
medication in transplant patients? (That is, are there any particular steps in the medicines 
administration process where you think things are likely to or could go wrong?) 
I think one area is confusion between once daily and twice daily preparations so prograf and 
advagraf. People not appreciating that if they switch to advagraf they need to take same 
overall dose which would be twice the dose of prograf at that time. Issues relating to generic 
prescribing and issues relating to timing of administration of immuno-suppression. Issues 
regarding levels and when levels are taken relative to when drugs are taken and also people 
prescribing medications like antibiotics who are unaware of the effect that could have on the 
levels of CNI‟s for example. 
2. The nurses have a lot of responsibility and are busy around the ward. What impact do you 
think this could have on drug administration to patients? They might make mistakes and 
give the wring drugs or the wrong dose to people. Also the timing of administration may 
be delays in when people get their medication if they are busy. 
Do you think procedures are always followed? 
I think the nurses do their best to follow procedures and to minimize errors but it‟s not 
infallible. 
3. After being discharged, do you think the patients go home with enough knowledge to 
safely take their immuno-suppressants in the way they were intended?  
Most patients. 
What are the risks if patients are not educated?  
That they‟ll take the wrong immuno-suppression at the wrong time. That they‟ll not take their 
medication when they‟re supposed to, that they‟ll not know that they need to be careful about 
other medications interacting with immuno-suppressant. And that they would attend follow 
ups appropriately. 
Who educates the patient and is there a record of this? 
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I think the doctors nurses and pharmacists will all and transplant co-coordinators will all be 
involved in educating the patient. And I think probably the documentation would be variable. 
Do you know if there‟s any written information given to the patient? 
I think they get written information. They should routinely get written information about their 
immuno-suppressants. 
4. How important do you think patient adherence to drug regimen (compliance) is in this 
group of patients? 
Very important 
5. Do you think most transplant patients do adhere to their drug regimens? If not, why do 
you think that is? 
I think most don‟t 100% because of impact upon their lifestyles, genuine mistakes, 
forgetfulness, stigma attached and wanting to de-medicalise their problems. 
Prescribing  
1. What do you think the risks are in the prescribing of immuno-suppressants to transplant 
patients? 
Patient getting drug toxicity, being over immuno-suppressed and patients being under 
immuno-suppressed and being at risk of rejection. 
2. Monitoring is important in the use of immuno-suppressants, and blood tests are taken 
frequently. How are the results of the blood tests taken into consideration at the time of 
prescribing? 
Well we look at renal function in terms of creatinine, looking at the full blood count in terms 
of if there is any bone marrow suppression and also looking at the drug levels in order to 
determine if someone is receiving too much or too little immuno-suppression. 
3. Who (which grade of doctors) does most of the prescribing of immuno-suppressants on 
the ward? 
I think in clinic that is either consultant or registrar, on the ward then the decision is usually 
consultant or registrar although the signature in terms of the prescription may be someone 
more junior. 
4. How important do you think it is that the GP is well informed about what happens in the 
clinic and hospital?  
Very important 
What are your perceptions of consequences if the GP is not being informed? 
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It increases the likely hood of the patient receiving inappropriate immuno-suppression. 
5. In your opinion, what information needs to be provided to the GP? 
They need to understand the rationale for immuno-suppression and they need to appreciate 
that other medication can interfere and they should feel that we in the renal unit want to be 
contacted if they have any questions at all. I much rather be contacted by something trivial 
rather that have to deal with the consequences and mistakes later on. 
6. What information is provided to the GP about current drug regimen at discharge, and 
eventual changes in drug regimen and how is this documented? 
When the patient is discharged after having a transplant they get a discharge letter, a letter 
after every admission and they get a letter after every clinic appointment. If changes need to 
be made sooner or more urgent changes then there may be communication by telephone. 
7. At the time of prescribing, do you think drug interactions are taken into consideration? 
In hospital and transplant unit, yes. GP: not always 
8. Would you consider drug interactions to be an important issue in the administration and 
prescribing of immuno-suppressants? 
Very important. 
9. If at a point in time, the prescribing doctor is uncertain about anything regarding 
prescribing of the drug, what action do you think the doctor will take?  
Within renal transplant unit, the doctor would either ask a more experienced doctor or would 
look up in the renal drug handbook or both. 
Participant 3; senior doctor 
Administration  
1. What do you think are high risk areas in the administration of immunosuppressant 
medication in transplant patients? (That is, are there any particular steps in the medicines 
administration process where you think things are likely to or could go wrong?) 
Incorrect formulation, incorrect dose, inappropriate times of taking medication, incomplete 
(noise), poor compliance 
2. The nurses have a lot of responsibility and are busy around the ward. What impact do you 
think this could have on drug administration to patients? Do you think procedures are 
always followed? 
Incorrect timing- They can‟t go around and do the drug round at the appropriate time. 
Mistakes in drug prescription such that they get the dose wrong. If we switch between 
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advagraf and prograf, there may be confusion relating to that. If nurses are too busy to check 
what formulation of tacrolimus they‟re on then the wrong formulation may be provided. Do I 
think they always adhere to? No. 
3. After being discharged, do you think the patients go home with enough knowledge to 
safely take their immuno-suppressants in the way they were intended?  
Some but certainly not all and in fact we have a number who are clearly not able to take it 
appropriately and probably will never ever be able to take it appropriately. 
What are the risks if patients are not educated?  
Poor compliance in its broader sense leading to under immuno-suppression and over immuno-
suppression and it‟s not just the immuno-suppressant effects. We‟ve had people taking the 
wrong dose and having marked renal dysfunction with tacrolimus. 
Who educates the patient and is there a record of this? 
Nursing staff educate the patients with the involvement of pharmacy. There is a formal record 
and 3 step process. 
Is the patient given any written information? 
Yes 
4. How important do you think patient adherence to drug regimen (compliance) is in this 
group of patients? 
Very 
5. Do you think most transplant patients do adhere to their drug regimens? If not, why do 
you think that is? 
I think it‟s the degree of compliance rather than the absolute incompliance and people 
comply poorly for a number for reasons. Young patients may not comply because they‟re 
too busy doing other things, they think they‟re immortalized and by missing a few drugs 
it‟s not going to matter. They may be worried about the side effects of steroids. People 
used to get worried about the side effects of cyclosporine. In general as patients get further 
from their transplant, if they‟ve had no complications they probably feel that the immuno-
suppression is less important and compliance will drop off. It‟s easy to forget medications, 
I do it. If they are old, there may be confusion, and there may be difficulties with poly-
pharmacy. And as I said there are some people who I don‟t think ever come to grips with 
what medication they should be taking and why. And if they don‟t see it as vital, don‟t 
understand it, then compliance will be reduced so I don‟t think there‟s one factor, there‟s 





1. What do you think the risks are in the prescribing of immuno-suppressants to transplant 
patients? 
I suppose if we take tacrolimus there‟s getting the correct formulation, prograf versus 
advagraf. Incorrect doses, incomplete monitoring and failure to adjust appropriate with that. 
And not reducing immuno-suppression at the correct time. Immuno-suppression is at its 
greatest level immediately after a transplant, right after an episode of rejection, and should 
reduce over 3 month period, but often it doesn‟t or it doesn‟t do it in a timely fashion. There‟s 
a possibility of drug interactions. We‟ve had patients that have been treated with 
erythromycin for chest infections even on the transplant ward. Very high tacrolimus levels 
after that. 
2. Monitoring is important in the use of immuno-suppressants, and blood tests are taken 
frequently. How are the results of the blood tests taken into consideration at the time of 
prescribing? 
Not quite certain about the question… I suppose we do have a protocol which guides the 
tacrolimus level, and what targets are made for different times out from the transplant. Do 
understand it‟s a guide, so on the liver side we probably use lower levels than are in the 
protocol and there are a number of factors which will feed into any decision about 
switching the tacrolimus dose, duration out from transplant and ongoing complications, 
renal dysfunction, any problems with hyperkalemia. The other immuno-suppressant that 
we may be using such as MMF versus azathioprine, so the global burden of immuno-
suppression and what we‟re trying to achieve. What the indication for transplant was. 
Hepatitis C we try and run lower rather than higher levels, but not so low that we get 
rejection. Patient age may come into it again. Higher levels for younger patients and of 
course what we think is happening with the liver function test. So the level we get back is 
not an absolute trigger for a response in changing the tacrolimus dose, it‟s another bit of 
information along with the rest of the patients to make a decision for dose modification. 
3. Who (which grade of doctors) does most of the prescribing of immuno-suppressants on 
the ward? 
Prescribing and writing the cardex'es; registrars and FY2‟s 
4. How important do you think it is that the GP is well informed about what happens in the 
clinic and hospital? What are your perceptions of consequences if the GP is not being 
informed? 
I think it is very important. Partly „cause they‟re terrified of immuno-suppression and really 
worried about what it is and what it means and making any changes and they probably 
shouldn‟t be making any changes. I think the important thing for them is to be aware what the 
drug is, what the side effects are and adverse drug reactions they should be looking out for 
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and being aware of drug interactions for their own safe prescription. So, not prescribing a 
macrolide antibiotic in the setting of a chest infection. 
5. In your opinion, what information needs to be provided to the GP? 
All GPs should have or do have access to shared care protocols for most of immuno-
suppression. It‟s historical; we don‟t actually have a shared care protocol for azathioprine. 
That‟s historical, it‟s been used for so long we‟ve not developed one for transplantation alone. 
So they have information from there, they need timely knowledge about what immuno-
suppression they‟re on, I suppose what plans we would ordinarily have for changing immuno-
suppression and what was expected from them. Do they always get it? I don‟t think so. 
6. What information is provided to the GP about current drug regimen at discharge, and 
eventual changes in drug regimen and how is this documented? 
Not enough, I suspect. I suspect we don‟t document it. Answer is I don‟t know. 
7. At the time of prescribing, do you think drug interactions are taken into consideration? 
Here in the unit? Yes. 
8. Would you consider drug interactions to be an important issue in the administration and 
prescribing of immuno-suppressants? 
Yes 
9. If at a point in time, the prescribing doctor is uncertain about anything regarding 
prescribing of the drug, what action do you think the doctor will take?  
Will take or should take?  I suppose depending on the time of day and need to find the 
answer, the BNF is available. If not; one of the transplant pharmacist, if not; if it‟s a 
middle grade doctor; then one of the senior transplant clinicians. 
Participant 4; senior nurse 
Administration 
1. What do you think are high risk areas in the administration of immunosuppressant 
medication in transplant patients? (That is, are there any particular steps in the medicines 
administration process where you think things are likely to or could go wrong?) 
I think the fact that sometimes patient education is not the best and they don‟t understand the 
importance of them. And we have old patients who, I wouldn‟t say they‟re non compliant… 
the majority of patients are, but you have the odd patient that perhaps doesn‟t understand. We 
had one particular gentleman I can think of that relied on his family to do his medication. So I 
think there are dangers there, and perhaps they need a bit more education and input on the 
importance of them. There can be dangers there, if they don‟t understand the rationale behind 
why they need to take them really. 
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2. The nurses have a lot of responsibility and are busy around the ward. What impact do you 
think this could have on drug administration to patients? Do you think procedures are 
always followed? 
I think as the years have gone by, pharmacy…we have a wonderful pharmacist on the ward 
don‟t get me wrong, but she‟s one person for many people, and as the years have gone on, 
nurses take on a wee bit more of this role, a wee bit more of that role..and pharmacy…I‟ve 
been away from 18 months and come back, and I‟m amazed that you have to now count the 
tablets on the script, you have to administer to the patients, you have two of you to check, 
which is fine..ehm, you have to dispense the medicines yourself which we‟ve been doing for a 
few years, whereas before, you did a letter than went to pharmacy so that was taken away 
from you. I think in transplant, a huge part of our role is to educate the patients on their needs 
and for years patients have been doing self medicine in transplant, so it is very much part of 
our role, but a huge input from pharmacy would be far better for patients because they‟re 
getting the correct advice. Because you guys have the experience and knowledge that we 
don‟t. And also we don‟t have the time to sit with patients and educate them the way that they 
ought to have, we don‟t always have time to do it the way that it should be done.  
3. After being discharged, do you think the patients go home with enough knowledge to 
safely take their immuno-suppressants in the way they were intended?  
I would hope so, yes. There‟s one particular gentleman I‟m thinking about. We decided that 
he needs a dosette box for his MMF and tacrolimus, so that they could go in there. We would 
send patients home if we didn‟t feel it was safe bit at the same time we can‟t keep them in 
hospital just „cause they don‟t have the knowledge of their tablets, but I think education 
would certainly more what the patient needs-from the pharmacy team.  
What are the risks if patients are not educated?  
The first thing is rejection because it‟s important to take their immuno-suppressants to prevent 
their organ rejection. It is life threatening of they don‟t comply.  
Who educates the patient and is there a record of this? 
Well yeah, the nurses educate them and the transplant co-ordinators have a big role with 
medication. I suppose we do have it documented. We have paperwork for patients that do 
self-med and we have stage 1, 2 and 3. We can consent them if we deem them fit to do self 
meds unsupervised so we do have documentation to support the safety of things and we also 
document it in the nursing notes that patients are on self med and things like that. 
Is the patient given any written information? 
Yes, when they go home they have their green books that tell them what the medication is for, 
why their taking them etc. They have it all written down, and how often they take them and 
what they take them for.  
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4. How important do you think patient adherence to drug regimen (compliance) is in this 
group of patients? 
It‟s paramount. If you do nothing else, at 10 in the morning you do your tacrolimus right, and 
ten at night.  
5. Do you think most transplant patients do adhere to their drug regimens? If not, why do 
you think that is? 
Oh yes, evidently they do. You get so many patients that are so grateful for having given 
them their life back. You have an odd patient, that, I‟m not saying they don‟t comply but 
it depends on the culture of people as well. We have one gentleman and his culture is that 
his family does everything for him. He‟s a young man, he‟s fit, he‟s well, he‟s healthy, 
he‟s nursed backed to health fully independent, but I know his family will do everything 
for him.  
Prescribing 
1. What do you think the risks are in the prescribing of immuno-suppressants to transplant 
patients? 
I would hope it never would but it‟s like with any drug administration, the writing is eligible 
and if you don‟t have the knowledge behind what you‟re doing, that‟s a danger already. But 
the majority of nurses do have the knowledge of what they‟re dispensing and if they don‟t, 
they have the BNF to look it up. 
2. Monitoring is important in the use of immuno-suppressants, and blood tests are taken 
frequently. How are the results of the blood tests taken into consideration at the time of 
prescribing? Not asked as not relevant for nurse. 
3. Who (which grade of doctors) does most of the prescribing of immuno-suppressants on 
the ward? 
FY1 but in transplant FY2, under supervision of consultants etc 
4. How important do you think it is that the GP is well informed about what happens in the 
clinic and hospital? 
Very important. Everybody who has responsibility for the patients has a bit of knowledge 
about what is going on. Transplant is so specialized, there‟s enough people out and about 
there, and enough information for people to be able to understand how important it is that 
these patient have things just so, but it‟s very evident, that if any patient anywhere in Scotland 
becomes unwell even if they have a chest infection, or a fractured hip, no matter what‟s 
wrong with them: if they‟ve had a transplant, they come back to us because they are very 
specialized patients. And that‟s nice, you get to follow up, but yes the GPs are very good at 
lifting the phone and asking for advice, as are relatives and patients. You‟re a resource to 
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everybody really. But yeah, I think there‟s quite a lot of good information that goes out to 
GPs. 
What are your perceptions of consequences if the GP is not being informed? 
I can‟t answer that. I‟m not at the other end. I don‟t understand fully what the information 
lacking would be. I would hope there was enough information for them and if not they would 
have to phone. 
5. In your opinion, what information needs to be provided to the GP? 
They always have the discharge script with their letter, with their medication. The GP has a 
more detailed letter that the registrars and the consultants have written. They give information 
about what‟s been happening so they should be well enough informed. Now in Lothian we 
have tracks so GPs can access blood results and things from the track statement 
6. What information is provided to the GP about current drug regimen at discharge, and 
eventual changes in drug regimen and how is this documented? Did not ask question as 
she answered that above. 
7. At the time of prescribing, do you think drug interactions are taken into consideration? 
I would hope so. I lot of nurses are very experienced. We have the knowledge that give 
certain drugs together. I think they (the nurses) would know because they deal with it those 
drugs every day. 
8. Would you consider drug interactions to be an important issue in the administration and 
prescribing of immuno-suppressants? 
Absolutely 
9. If at a point in time, the prescribing doctor is uncertain about anything regarding 
prescribing of the drug, what action do you think the doctor will take?  
They‟re very good at phoning the registrars who have the advice. Our pharmacist is very 
much involved with the ward rounds and she‟s on the ward every day and they all know her 
which I‟m amazed at which is fantastic. So she‟s our first resource as well as the senior 
doctors as well. And there‟s always the out of hours pharmacy if you every need advice, or 
anyone else in the other end of the phone which would put you in touch with them. 
Participant 5; junior nurse 
Administration 
1. What do you think are high risk areas in the administration of immunosuppressant 
medication in transplant patients? (That is, are there any particular steps in the medicines 
administration process where you think things are likely to or could go wrong?) 
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In the timings when we give it. If we don‟t have in prescribed on time, that can go wrong 
and they‟re getting it late. Also with giving it at 10, you might not give it bang on ten if 
you get tied up, so that‟s really the major issues. 
2. The nurses have a lot of responsibility and are busy around the ward. What impact do you 
think this could have on drug administration to patients? Do you think procedures are 
always followed? 
We try to follow them, but if you get tied up with a patient and you can‟t get away or if 
something major happens, it is pretty hard to give it on time. 
3. After being discharged, do you think the patients go home with enough knowledge to 
safely take their immuno-suppressants in the way they were intended?  
Yes, they‟re seen by us (the staff nurses), the doctors and pharmacists as well and the 
pharmacists are pretty good at giving the talks before they go home, so yeah I think so. 
What are the risks if patients are not educated?  
If they‟re not educated the risks are: are they taking the right dose at the right time and not 
with their other tablets „cause they have interactions. You do sometimes see them coming 
in and they‟re just swallowing them with every other tablets they‟re due. 
Who educates the patient and is there a record of this? 
Staff nurses educate them, there‟s a record of that when we give the self medication, then 
the pharmacists educate them as well and they write something in the notes about doing 
so. 
Is the patient given any written information? 
Yes, when they get their self medication, we hand out education sheets and they can read 
that in their leisure and we give that out before we sign so they can‟t do it without reading 
the information we give them. We also give that to the relatives if required so they are 
educated about the importance of the tablets too. 
4. How important do you think patient adherence to drug regimen (compliance) is in 
this group of patients? 
It really depends on the patients and their attitudes. Some patients are fantastic and they‟ll all 
say bang on ten o‟clock and other patients are less likely to want to take their tablets. It‟s all 
down to the patient really. 
5. Do you think most transplant patients do adhere to their drug regimens? If not, 
why do you think that is? 




1. What do you think the risks are in the prescribing of immuno-suppressants to transplant 
patients? 
Getting the bloods to the lab on time, the labs to process it in time, and then the doctors to 
prescribe it in time. There‟s been numbers of times when you‟re chasing everyone up just to 
try and get the dose prescribed so that is really where things can go wrong. 
2. Monitoring is important in the use of immuno-suppressants, and blood tests are taken 
frequently. How are the results of the blood tests taken into consideration at the time of 
prescribing? Not asked as not considered relevant for a nurse. 
3. Who (which grade of doctors) does most of the prescribing of immuno-suppressants on 
the ward? 
It‟s our senior house officer or registrars who do it. 
4. How important do you think it is that the GP is well informed about what happens in the 
clinic and hospital?  
It is really important because the GP sometimes aren‟t aware of the Tacrolimus and prograf 
and everything else. They don‟t realize the importance of that to the transplant patients (noise) 
What are your perceptions of consequences if the GP is not being informed? 
The GP can change the tacrolimus, too high dose, too low dose and they lose their graft. 
5. In your opinion, what information needs to be provided to the GP? 
They need an education pack about tacrolimus etc and the importance, the risk factors with it, 
just a bit more education for them I suppose because it‟s a specialized drug. 
6. What information is provided to the GP about current drug regimen at discharge, and 
eventual changes in drug regimen and how is this documented? 
When we give the discharge letter, it should say in it that they shouldn‟t touch the tacrolimus 
and that it will be done at clinic, but I don‟t know if it that actually does happen. Also we 
have a green book that we give out to patients in self medication. It does state in that for the 
GP not to alter the dose without corresponding into the hospital. 
No don‟t know how this is documented. 
7. At the time of prescribing, do you think drug interactions are taken into consideration? 
Yeah, that‟s why it‟s prescribed at 10 o‟clock so it‟s not interacting with the morning meds or 
the food. And again it‟s down to the doctors to see if they‟re on any tablets that interact. 
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8. Would you consider drug interactions to be an important issue in the administration and 
prescribing of immuno-suppressants? 
Definitely, if you don‟t watch what you‟re prescribing, it won‟t work as well. 
9. If at a point in time, the prescribing doctor is uncertain about anything regarding 
prescribing of the drug, what action do you think the doctor will take?  
They quite often phone our pharmacists that we have in transplant. The pharmacists are 
brilliant, so they‟ll tell you. 
Participant 6; senior doctor 
Administration  
1. What do you think are high risk areas in the administration of immunosuppressant 
medication in transplant patients? (That is, are there any particular steps in the medicines 
administration process where you think things are likely to or could go wrong?) 
I suppose there‟s the predictable and unpredictable consequences of prescribing immuno-
suppressants. You‟re immuno-suppressing patients so you‟ve got the risk factors like 
infection, malignancy, drug toxicity, graft dysfunction. You‟ve got the unpredictable 
consequences due to either prescribing errors or patient adherence to prescribed regimes. 
Drug interactions, intercurrent illnesses, infections and things like that. So you know it can be 
a consequence of inadequate communication, miscommunication or insufficient 
communication. 
2. The nurses have a lot of responsibility and are busy around the ward. What impact do you 
think this could have on drug administration to patients? 
Do you think procedures are always followed? 
I think patient administration is only a small part of the whole patient journey, but yes, very 
definitely it can have an effect. We see that the timing of prescribing of immuno-suppressants: 
we advocate for drugs like prograf or neoral 10pm and 10am and that doesn‟t fit in with the 
drug prescribing round, so instantly there is a problem. I think it‟s very important to 
encourage patients as early as possible to take on the responsibility for their medications. 
They need to have the information and understanding to be able to do that. I think there are 
other risks obviously with many patients in a ward and obviously drug errors in terms of 
administration but I think those can be reduced, particularly where patients are keeping their 
own drugs rather than having trolleys. So I think there are things that are improving but a 
busy ward is not particularly conduce environment for safe prescribing. 
3. After being discharged, do you think the patients go home with enough knowledge to 
safely take their immuno-suppressants in the way they were intended?  
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Some patient do, some patients don‟t. Patients are all individuals and it‟s very clear to us in 
the clinic that some have got a very good understanding and are very on top of it, whilst 
others don‟t, so having any set protocol pathway for educating patients about medication has 
to respect those patients‟ differences. Some find it incredibly hard and there are patients who 
clearly are never going to cope. They may even come into a transplant relying on dosette 
boxes and therefore they just don‟t have the capacity to take on the intricacies of prescribing 
immuno-suppressants. I think you have to adjust what you do for individual patients. I think 
it‟s important that they have lots of different sources of information so that as well of verbal 
communication, they need written communication. I think one of the big issues about 
transplant patients particularly the prescribing of CN and phosphatase inhibitors is that they 
change so frequently, it‟s important that that information keeps up with the patient and that is 
a source of problems. What we often see is that by the time the discharge letter reaches the 
GP, the patient has already been to the clinic once or twice and a couple of dose changes have 
already happened and suddenly the GP is hit with two bits of information coming in at the 
same time albeit with different dates but different doses and that‟s a frequent query.  
What are the risks if patients are not educated?  
There are the obvious risks. Patients‟ adherence depends on physical and perceptual ability to 
take the drugs. From the perceptual side of things they have to understand what the immuno-
suppressants are for, what the benefits are and the impact if they stop taking it. They also have 
to be confident that these drugs aren‟t going to do significant harm. Often we see patients who 
don‟t want to take them because they think it‟ll cause cancer or something and clearly you 
talk about the risks but you‟ve got to educate them on the whole risk benefit analysis. The 
patients have access to the drugs as well so they‟ve got to be able to have either a supply 
home with them that reflects the prescription they‟ve been given. A classic example is 
discharge on prograf 5 mg twice a day and when they come to the first clinic appointment, the 
dose needs to go down to 4,5 mg and suddenly they need 1,5 rather than the 5‟s and they 
don‟t have the right tablets and the delay in getting the correct tablets from a pharmacy is too 
long so it is physical reasons and perceptual reasons why they may not be able to take the 
tablets like they‟re meant to. 
Who educates the patient and is there a record of this? 
There‟s a formal self medication programme which is documented. I have some concerns that 
it is not. It‟s like many of these check lists; you can tick boxes, but it doesn‟t necessarily mean 
that things are actually happening as you think they are. We see patients who have passed 
through the self med programme, and come and clearly don‟t understand and I think that 
comes back to what I was saying with individual patients‟ need to be treated in different ways 
but the education continues and we reiterate a lot of the purpose and function and reasons 
behind the immuno-suppressants when they come to the clinic and that‟s not formally 
documented but it happens. 
Is the patient given any written information? 
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Yes the patient should both have the little green book with has the lists of tablets in it and they 
should also have a copy of their discharge script  
4. How important do you think patient adherence to drug regimen (compliance) is in this 
group of patients? 
Critical, very important. 
5. Do you think most transplant patients do adhere to their drug regimens? If not, why do 
you think that is? 
Yes I think they do. That‟s probably credit to the education they do get. Most patients that 
leave hospital I expect don‟t adhere very well, but the transplant population do have that extra 
education. Certainly when we monitor the CNI levels, they‟ve gone down as we would wish. 
On the whole I think patient adherence is very good and patients are anxious enough about it 
that they will phone us up and ask. In the early days, on the whole they‟re good, but there are 
clearly patients who months or years down the line who start to fall by the waste side and it‟s 
not just adhering with drug regimes, it‟s tending follow up clinic visits. Many aspects of the 
care and these are often patients we don‟t see because they don‟t come to the clinic, and they 
are a worry and they lose their graft. 
Prescribing  
1. What do you think the risks are in the prescribing of immuno-suppressants to transplant 
patients? 
Overall under prescribing and over prescribing. You‟re inducing potential CNI toxicity, graft 
dysfunction, opportunist infection. Under prescribing you‟re running the risk of potential 
rejection. The prescribing is dependent on a number of factors; measured drug levels, graft 
function, timing of blood tests: we interpret blood tests as being a 12 h trough and often we 
say to patients what time did you take your tablets last night and you‟ve seen them in clinic 
and you have to accept and recognise that the 12 h through actually is a 10,5 h or 14 h level. It 
may not fit exactly and you have to take a bit of a guess and there may be other things like the 
patients has got diarrhea and that increases tacro (tacrolimus) absorption so you can have 
levels that are not reflecting what you hoped they would. 
2. Monitoring is important in the use of immuno-suppressants, and blood tests are taken 
frequently. How are the results of the blood tests taken into consideration at the time of 
prescribing? 
Very much so. Patients that have been to clinic this morning, I‟ll get their blood results and 
usually 80 % of the time, I‟ll get their tacrolimus levels back this evening and if they need a 




3. Who (which grade of doctors) does most of the prescribing of immuno-suppressants on 
the ward? 
As inpatients in the ward: predominantly consultants because there‟s a daily ward round and 
then when the bloods including the drug levels come back in the evening there‟s usually a 
consultant who touches base with the SHO or registrar and they‟ll go through any changes in 
the drugs. But it‟s certainly minimum registrar level. 
4. How important do you think it is that the GP is well informed about what happens in the 
clinic and hospital?  
Very important, because in effect they‟re the ones doing the prescribing. That is also a source 
of problem having to convey information to the GP, and that prescription then has to go to 
pharmacy, and pharmacy then have to dispense the medication and each of those steps 
induces delay and potential error. I think GPs get anxious about it „cause it‟s not something 
that they are handling very often and also they get quite anxious about the rapid dose change 
because it‟s something that their systems don‟t cope well with. After each clinic visit a letter 
is generated. Initially it‟s 3 times a week and by the time the letter gets to the GP they might 
be confronted with two letters with different doses. 
What are your perceptions of consequences if the GP is not being informed? 
Patients don‟t get the right dose. Patients find it frustrating, they go to the GP and GPs aren‟t 
happy to prescribe the drugs so they‟ll often end up coming back to us and asking for a 
hospital prescription so it‟s a number of adverse consequences. The kind of thing that really 
helps is if we see a patient, and the letter is dictated and the letter is typed ideally tomorrow, 
they‟re out quickly, but if there‟s a problem with secretarial staff it can be ten days before the 
letter is done and by then the patient may have been seen 2-3 more times so I think what 
really helps is if the patient are well informed and they have access to a range of tablets sizes 
then you can actually do those dose adjustments without it having to go directly through the 
GP and the GP could then just be informed of the changing dose. I think it‟s really 
problematic if you‟re having to wait for the patient to go to the GP. It can‟t work that way, so 
the patients needs to have access to a range of different tablets so that they can make a dose 
change immediately tonight reflecting a high level this evening or something like that, and not 
wait for GP next week. 
5. In your opinion, what information needs to be provided to the GP? 
Contemporaneous, up to date list of medications  
6. What information is provided to the GP about current drug regimen at discharge, and 
eventual changes in drug regimen and how is this documented? 
They get a copy of the discharge letter which is given to the patient and GP and other relevant 
medical staff. That‟s then followed up quite rapidly in transplant patients with an early clinic 
review. The clinic letters with all have copies of the drugs from proton. 
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7. At the time of prescribing, do you think drug interactions are taken into consideration? 
Yes I would hope so. There are going to be occasional ones that will be missed but the 
important ones like diltiazem, quinolone antibiotics, antifungals etc are always considered  
8. Would you consider drug interactions to be an important issue in the administration and 
prescribing of immuno-suppressants? 
Yes they are but if you‟ve got a patient who is on a regular dose of diltiazem, then you just 
need to adjust the prescribing dose. It‟s a safe and constant interaction therefore you run with 
it. It doesn‟t stop you from prescribing, but you just need to factor it in your initial dosing. 
9. If at a point in time, the prescribing doctor is uncertain about anything regarding 
prescribing of the drug, what action do you think the doctor will take?  
I would hope that they would look up or seek further information from other people, books 
etc. 
Participant 7; senior doctor 
Administration  
1. What do you think are high risk areas in the administration of immunosuppressant 
medication in transplant patients? (That is, are there any particular steps in the medicines 
administration process where you think things are likely to or could go wrong?) 
I think in the early periods the dangers with immuno-suppressants are infection, our own 
experience the problems have tended to be in the first couple of months when we‟ve given 
MMF and high dose CNI particularly in people who have been re-transplanted because of an 
immune mediated liver injury. I think we‟ve run into one or two infective problems at that 
time and one or two bad CMV‟s in that situation and pneumocysts as well. In terms of long 
term effects the major problems we‟ve seen have been with renal dysfunction and with 
malignancy. I think now we probably reduce immuno-suppressants more appropriately as 
time goes on: When people are 3-4 years out, we quite happy to run with just Tacrolimus at a 
level of 3-4 and we‟re more likely to stop AZA or other agents as time goes on. In terms of 
the people who need more immuno-suppression..the younger who‟ve had rejection episodes, I 
think we use more MMF now and we have also started to use combinations involving 
sirolimus where the CNI are limited because of the renal toxicity so we can‟t give big doses of 
CNI into the patients, we‟ve used in a number of patients now sirolimus in combination with 
either tacrolimus or cyclosporine. I‟m not sure if that‟s going to be of benefit in the longer 
term but certainly for the one or two patients we‟ve struggled and they‟ve lost grafts from 
immune injury they seem to be working relatively well in combination. It is a very immuno-
suppressive combination. I can remember one slightly older patient that we gave that 




2. The nurses have a lot of responsibility and are busy around the ward. What impact do you 
think this could have on drug administration to patients? 
Do you think procedures are always followed? 
I think probably 90 % of the time they do get their meds on time but hospitals being busy 
places and people being sick from time to time there will be a slight deviation in the time 
given. But on the whole I think they do. 
3. After being discharged, do you think the patients go home with enough knowledge to 
safely take their immuno-suppressants in the way they were intended?  
I think there‟s probably 3 sorts of patients. There are people who are very keen on knowing 
all about their meds, and what it‟s for and they‟re very regimented in taking it. They ask 
questions, and read up and want to know more. There are people who don‟t really want to 
know anything but are quite specific in obeying orders. They understand that they have to 
take their meds and they‟ll stick to what they‟re told but don‟t really understand that much 
about what they‟re for, but they know that they‟re important and that‟s all that matters to 
them. And then there are people who kind of fall in between who know a little bit and know 
that they‟re important but aren‟t that vigilant in taking their meds in terms of their adherence 
to the prescription. In my experience they tend to be the younger people who are a bit too 
interested in other things than taking care of their health. 
What are the risks if patients are not educated?  
Graft loss if they don‟t take their meds for a prolonged amount of time. I think everybody 
tries to stress to them the importance of doing that, until they physically feel either sickness or 
are faced with the stark realisation that theirs livers not working. I think that‟s a wake-up call. 
Up until that point I think you can educate them and tell them as much as you want and ii 
don‟t think it‟s going to make that much of a difference. 
Who educates the patient and is there a record of this? 
There are different phases of self medication and there is a record they go through. It‟s done 
by the nurses and then the pharmacists make sure that they know what the tablets are. 
Are they given any written information? 
Yes they are. I‟ve seen the sheets. 
4. How important do you think patient adherence to drug regimen (compliance) is in this 
group of patients? 
I think liver transplant is one of the more important areas of taking medication. If you miss 
the odd tablets here and there but if you miss the immuno-suppressant or prophylaxis like 
valganciclovir that can be very important. It is an important group of patients that are 
reasonable regular in taking their medication. 
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5. Do you think most transplant patients do adhere to their drug regimens? If not, why do 
you think that is? 
It depends on how you define adherence. If you mean adherence 90 % of the time they take 
their tablets around 1 hour around when they‟re suppose to, I‟d say yes. If your adherence is 
strict I‟d say no. 
Prescribing 
1. What do you think the risks are in the prescribing of immuno-suppressants to transplant 
patients? 
The risks are different formulations of the same drug. MMF which is cellcept which is 500 
and then there‟s MMF myfortic which is a different dose. There is tacrolimus in the form of 
prograf and advagraf and now generic. Cyclosporine is neoral and generic as well. So there 
are issues with the formulation of the same medicine and there are also issues when you 
switch from one immuno-suppressant to another, because tacrolimus prograf is twice a day 
and if you switch to something like sirolimus which is once a day and we‟ve had issues with 
people taking sirolimus twice a day because they thought it was a direct change from 
tacrolimus. The other issue that we‟ve had has been people taking 5 mg instead if 0,5 mg of 
tacrolimus and also 5 times 5 mg, because you get prograf 1 mg tablets or 5 mg tablets and we 
had someone who took five 5 mg tablets so 25 mg and he got into major problems so I think 
there are issues in the dose itself, there are issues in the different formulations, and there are 
major issues when you switch from one immuno-suppressant to another, and the only way 
really that you get round that is by going over with the patient and writing it down in clinic, 
you have to go over that it‟s not suppose to be taken twice a day and make sure they 
understand that. Most of the time it works but in the occasional patient there is a problem. 
2. Monitoring is important in the use of immuno-suppressants, and blood tests are taken 
frequently. How are the results of the blood tests taken into consideration at the time of 
prescribing? 
Monitoring for through levels is really only done with the CNI and sirolimus. We get the 
results of the troughs of the CNI either the day of the tests or day after, sirolimus takes some 
time because it is sent away. So we look at the tests and if they are in-patients we modify the 
dose for the next day, if they‟re out patients then we have a follow-up meeting 2-3days after 
clinic, and if there is to be a change in dose it is written on the follow-up sheet and the co-
coordinator phones the patient to tell them of the change in dose so that doses are changed 
either by telephone by co-coordinator or by a change in the prescription on the ward. 
3. Who (which grade of doctors) does most of the prescribing of immuno-suppressants on 
the ward? 
The signing of the prescription is either done by the registrar or the junior doctor below, the 
foundation doctor, the (noise) and it is usually at the ward round at the instruction of the 
consultant physician. At the meeting on the ward round, we would discuss if there‟s a change 
115 
 
and if the discussion isn‟t there then it‟s usually at the bedside by the patients where we look 
at levels and decide. But the actual prescription is usually signed by one of the junior doctors. 
4. How important do you think it is that the GP is well informed about what happens in the 
clinic and hospital?  
Extremely important. One of the major difficulties we‟ve had in recent months and years is 
correspondence with the GP because typing and issues around discharge and clinic letters go 
behind. The patient hopefully know what they‟re taking, and there was a written document in 
the notes but there was no dictated letter to the GP so quite often the GP would be a few 
weeks behind what was physically happening. That can be a problem if the patient goes for a 
repeat prescription particularly if there‟s a change. If it‟s a switch then it‟s even worse 
because they‟re not aware. We‟ve had issues with that and I think we can probably be better 
at that. How will we do it I‟m not entirely sure unless the patient had it in their book and they 
took it with them and it was signed. 
What are your perceptions of consequences if the GP is not being informed? 
We‟ve not had any major consequences it just means a lot of running around for the GP as 
well. They will often phone and say that the patients tells me that the does have changed, can 
you fax me something to confirm this. I don‟t think it‟s translated into major problems in 
terms of treatment, I just think it‟s translated into problems for the time wasting for GP 
chasing us around. 
5. In your opinion, what information needs to be provided to the GP? 
Transplant is fairly specialized and I don‟t think the GP will want to know particularly why 
we‟ve changed doses etc. I just think they need to know the prescription and the dose. I think 
if there‟s a switch in medication, there needs to be some explanation to why the switch has 
taken place as well as the dose that is used, whether that dose will change in time of whether 
it‟s a fixed dose forever. So I think they‟d like to know if it‟s likely to change and over what 
sort of time period. 
6. What information is provided to the GP about current drug regimen at discharge, and 
eventual changes in drug regimen and how is this documented? 
Usually the clinic letters the present dose is given and if there is any changes it is given there 
as well. I‟m not sure of what everybody‟s practice is in terms of saying that a lot of drugs are 
going to be stopped at 3 months and altered. I usually say that at 3 months there will be 
significant changes and after that most people only remain on tacrolimus, CNI and AZA or 
MMF after that. I‟m not sure if there is any other formal information that is given to GP. This 
is documented through clinic letters. 
7. At the time of prescribing, do you think drug interactions are taken into consideration? 
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I think they‟re taken into consideration. They might not always be known. From the GPs point 
of view, they are reasonable good at calling us if they have a concern or if they‟re starting 
new meds. It‟s quite regular for them to phone and ask "is it ok if we give this?".But we‟ve 
been called out a few times particularly with antibiotics like clarithromycin or something like 
that where that hasn‟t been discussed with us and they‟ve been put on it. Not just by GPs but 
by other hospitals. So I think within the unit we‟re reasonable good, but as a whole it probably 
could be better.. 
8. Would you consider drug interactions to be an important issue in the administration and 
prescribing of immuno-suppressants? 
Yes  
9. If at a point in time, the prescribing doctor is uncertain about anything regarding 
prescribing of the drug, what action do you think the doctor will take? 
Speak to Kat. We do that quite regularly. We value certainly the pharmacists and they‟re quite 
rigorous at looking at things up so if we‟re uncertain I usually just speak to Kat. 
Participant 8; Transplant ward pharmacist  
Administration 
1. What do you think are high risk areas in the administration of immunosuppressant 
medication in transplant patients? (That is, are there any particular steps in the 
medicines administration process where you think things are likely to or could go 
wrong?) 
I‟d say high risk..it‟s probably in the prescribing..Oh sorry administration. So, there‟s the 
pressure that the nurses are under on the ward I guess. Drug rounds and not being distracted 
from that. And also with the tacrolimus with the different brands. 
2. The nurses have a lot of responsibility and are busy around the ward. What impact 
do you think this could have on drug administration to patients?  
It certainly could have a negative impact „cause there is a lot of pressure on them to do lots of 
different things as well as the drugs so ehm that can be detrimental. 
Do you think procedures are always followed? 
Laughs. Probably not but I don‟t think that‟s specific to transplant. I think you‟ll find any 
ward in this hospital is probably taking work-arounds or short-cuts or whatever. 
3. After being discharged, do you think the patients go home with enough knowledge 
to safely take their immuno-suppressants in the way they were intended?  
I may be quite bias because I like to think that they do because I make the point of speaking to 
patients. But I know that the nursing staff will spend some time with the patients and with the 
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liver patients, I will speak to them all about their new medicines and there‟s also a little 
section in the liver transplant-going home book. I think there‟s similar for renal as well so 
they probably do but maybe that could be improved on. 
What are the risks if patients are not educated? 
They just don‟t understand what they‟re taking, why they‟re taking it and they take it 
incorrectly 
 Who educates the patient and is there a record of this? 
I speak to them but I don‟t actually record it which is probably something I should make a 
point of writing in the notes that I have done so. 
Do you know if there is any written information given to the patient? 
Yeah, they all get the standard information-sheets about each of the individual medicines- 
4. How important do you think patient adherence to drug regimen (compliance) is in this 
group of patients? 
Obviously it is vital to the success of the graft. 
5. Do you think most transplant patients do adhere to their drug regimens? If not, why do 
you think that is? 
Yeah probably. There‟s probably..with the younger sets of patients, they maybe not taking 
their twice daily tacrolimus, they maybe not taking their evening dose but I suppose the other 
side to that is what‟s the significance of that. 
Prescribing;  
1. What do you think the risks are in the prescribing of immuno-suppressants to transplant 
patients? 
The risks would be „cause they could be toxic medicines, potentially toxic, just a lack of 
understanding of what‟s being prescribed. 
2. Monitoring is important in the use of immuno-suppressants, and blood tests are taken 
frequently. How are the results of the blood tests taken into consideration at the time of 
prescribing? 
Well for in-patients the bloods are reviewed every day and are then used when making 
decisions. For out-patients for liver anyway their bloods are reviewed together with the co-
coordinator and the doctor from that clinic and any changes made are communicated to the 
patients. So they are in my experience always used closely. 




Ehm..I would say 50/50 split between the registrar and the junior doctor but the registrar 
would probably be always prescribing the calcineurin inhibitor, the tacrolimus and that 
would always be with the consultant looking over their shoulder. Years ago it was only 
the consultant that wrote that prescription but that‟s not been like that for a while. But it 
is very closely looked at. 
4. How important do you think it is that the GP is well informed about what happens in the 
clinic and hospital?  
Yeah it is very important but I appreciate it can be quite tricky „cause some patients are 
changing a lot and obviously the specialist knowledge is here so it‟s keeping that information 
up to date with the GP can be difficult. 
What are your perceptions of consequences if the GP is not being informed? 
Well I guess..ehm…in terms of just making sure that their record is up to date and then the 
patient..does he know what he‟s taking because he‟s getting different stories between hospital 
or GP and if the GP starts any new medicines, are there interactions, all the information 
available for interactions and that type of thing. 
5. In your opinion, what information needs to be provided to the GP? 
Ehm. In terms of drugs? Just doses, formulations, the brand, the importance of brand 
prescribing. For tacro and cyclosporine, the current dose and any… I suppose it is tricky 
because a lot of it is managed here in the hospital, they‟ll be taking the steroids down and 
that‟ll be up to them. Patients are individuals. You can‟t just say to the GP in two weeks we‟re 
going to reduce the prednisolone, because we don‟t know what‟s going to happen in two 
weeks. Just making sure the GP has an idea if what will be.. should be happening. 
6. What information is provided to the GP about current drug regimen at discharge, and 
eventual changes in drug regimen and how is this documented? 
So when the patient is discharged, they get an immediate discharge letter. A copy of which 
goes to the GP. The patients themselves should also have the green book which you 
know..that‟s more for the patient and then what‟s meant to happen is a much more full 
discharge summary is typed dictated by the registrar which has details about all the operation 
and any other things and that has the meds on it. The shared care protocols are available 
online. We used to send out paper copies but just to keep it future proof, they‟re available 
online and GPs should be able to access them. Of course the other issue is that we‟re a 
national unit and shared care protocols only really apply in Lothian. 
7. At the time of prescribing, do you think drug interactions are taken into consideration? 
Yes 
8. Would you consider drug interactions to be an important issue in the administration and 




9. If at a point in time, the prescribing doctor is uncertain about anything regarding 
prescribing of the drug, what action do you think the doctor will take?  
I think if it‟s one of the juniors they‟ll speak to the reg (registrar) or a consultant and then 
they‟ll speak to pharmacy as well. In terms of interactions they‟re pretty good at referring 
back to us. 
Participant 9: Junior doctor  
Administration 
1. What do you think are high risk areas in the administration of immunosuppressant 
medication in transplant patients? (That is, are there any particular steps in the medicines 
administration process where you think things are likely to or could go wrong?) 
Ehm..I guess you could be giving the wrong dose and you‟d be giving the wrong medication. 
Most of our patients are on Tacrolimus, and sometimes there‟s the occasional patient on 
cyclosporine so that can get mixed up. Ehm..and some patients are on twice daily 
prescriptions whereas other people are on once daily so there could be mistake made with 
that. And I guess as for all drugs things can be given to the wrong person and prescriptions 
can be written incorrectly. 
2. The nurses have a lot of responsibility and are busy around the ward. What impact do you 
think this could have on drug administration to patients?  
I guess if they‟re busy they don‟t necessarily take as much care with things and if they‟re 
rushed and having to do different bits and pieces then things can be missed or given 
incorrectly. 
10. Do you think procedures are always followed? 
I‟ve only worked here for a week. From my experience the procedures seem to be quite well 
followed. 
3. After being discharged, do you think the patients go home with enough knowledge to 
safely take their immuno-suppressants in the way they were intended?  
I don‟t know what...I‟m not entirely sure what kind of education they get. Certainly from us 
they probably don‟t get very much information about safely taking their medication. I think 
most of that information comes from the pharmacist. We probably don‟t tell them anything at 
all really other than what dose to take so from my point of view we don‟t give them enough 
information. 
What are the risks if patients are not educated?  
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Well they‟re quite dangerous drugs. Drugs that have got quite a few side effects that can 
potentially be very serious. So if they take them incorrectly because they don‟t know the 
potential for these side effects. They don‟t know how to take them then that‟s potentially 
more hospital admissions or you know worse outcomes for the patient. And if they don‟t take 
them at all or take as much as they should then there‟s a possibility of rejection of their organ 
as well which is kind of a waste of what they‟ve been through.  
Who educates the patient and is there a record of this? 
I don‟t know but I assume that the pharmacist and I imagine the transplant co-ordinators 
probably have a bit to do with it as well. I don‟t know where the record of that would be. I‟ve 
never seen a record of education. I hope it happens! I just assumed that it did. 
Do you know if there is any written information given to the patient? 
I don‟t know. 
4. How important do you think patient adherence to drug regimen (compliance) is in this 
group of patients? 
Oh I think it‟s really important. „Cause the consequences of them taking their medication 
incorrectly or not taking their medication are so serious that it‟s really important that they do 
take it correctly and we have had people in who don‟t…who are not taking their medication 
properly who‟ve had  to come back into hospital..so the consequences of not doing it properly 
is serious. 
5. Do you think most transplant patients do adhere to their drug regimens? If not, why do 
you think that is? 
Ehm..I don‟t know. I assume..I think probably the ones we get back into hospital are the ones 
that don‟t comply so I don‟t really see the people who get on with it. It‟s probably 
difficult..It‟s difficult enough to take any medication but for something particularly immuno-
suppressants that have to be taken at the same time, have to have levels and things done, that‟s 
probably more difficult to take than a lot of normal kind of drugs. I‟m sure there are people 
out there who aren‟t it as they‟re prescribed but I don‟t necessarily see them so I don‟t know 
how common it is. 
Prescribing;  
1. What do you think the risks are in the prescribing of immuno-suppressants to transplant 
patients? 
Well for me, I don‟t have very much experience in it „cause I just started this job so I think the 
risks are that people who don‟t have experience in it are prescribing medications and we ask 
for advice from the senior doctors about it and we always discuss what‟s going on but 
sometimes, occasionally people get missed out on the ward round or whatever and their 
immuno-suppressants don‟t get prescribed then. And then later on maybe over night, they 
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realise that they‟ve not been prescribed and doctors coming on who don‟t know patients, 
don‟t know the drugs, don‟t know what their levels are, and they‟re prescribing medication. 
So I think sometimes things get missed a bit, but I think asking advice from senior doctors 
and pharmacist is the best way not to cause any harm, hopefully! 
2. Monitoring is important in the use of immuno-suppressants, and blood tests are taken 
frequently. How are the results of the blood tests taken into consideration at the time of 
prescribing? 
So we do blood tests on Monday, Wednesday and Friday for the immuno-suppressants here 
and then we‟d look at the test results before we‟d prescribe the following days‟ immuno-
suppression. But like last week there was a problem in the lab and we didn‟t get any levels or 
between Monday and Friday, the Wednesday set, went didn‟t get any levels at all. So we were 
a bit kind of blindly prescribing there so I guess that‟s one of the dangers; you‟re relying on 
the lab to work and us to get the results back in time to prescribe it. 
3. Who (which grade of doctors) does most of the prescribing of immuno-suppressants on 
the ward? 
Oh it‟ll be me. So I‟m an FY2. I think I probably do most of the actual prescribing. Most of 
the time I do what I‟ve been told to do or making adjustments that have been discussed with 
other people for any kind of immuno-suppression or any other kind of medications. But in 
terms of actually prescribing it, it‟s usually me. 
4. How important do you think it is that the GP is well informed about what happens in the 
clinic and hospital?  
I think it‟s really important because the GPs are kind of an everyday link with the patients. 
The patients can see them kind of in between clinics and things and if they don‟t know how 
much the patient is meant to be taking then that can cause all sorts of confusion and then they 
might need to contact the hospital to find out how much they should be on. And then the GP 
is probably quite useful to monitor that they‟re actually taking the medications so I think there 
needs to be quite good communication with the hospital, the out-patient clinic and the hospital 
to make sure everyone knows what‟s going on. And it‟s quite scary when you‟re a GP to deal 
with patients that are transplant patients because they‟re so special and all the drugs are odd 
and not stuff that you deal with all the time so I think it‟s important to let the GPs know as 
much as you can so that they‟ve got a better idea of what‟s happened and how much 
medication they‟re on. 
What are your perceptions of consequences if the GP is not being informed? 
Well if the patient is ill with another problem. If they‟ve got an infection or something then 
it‟s important that the GP knows about their immuno-suppression and how much immuno-
suppression they‟re on. I think they need to know kind of what they‟ve already been taking 
and especially with interactions as well with other medications if they want to prescribe 
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something else. So I think lots of things could go wrong of they weren‟t informed of the 
medication. 
5. In your opinion, what information needs to be provided to the GP? 
From an out-patient clinic I think they need to know exactly what medication they‟re on and 
what times the patient should be taking them and what dose they‟re taking at the minute and 
the arrangements for the monitoring. I‟m not sure whether it gets done. I presume it gets done 
in between by the GPs or maybe it gets done just in the clinic..I don‟t know „cause I‟ve not 
been in clinic but it‟d be important to know what monitoring there‟s going to be and they 
probably need to know a contact to get in touch with if there are any problems with it so that 
they‟ve got someone to ask questions to „cause like I said it‟s not something that you‟d 
(noise) everyday. 
6. What information is provided to the GP about current drug regimen at discharge, and 
eventual changes in drug regimen and how is this documented? 
So at discharge we send out an immediate discharge letter with the patient. I don‟t know if 
you‟ve seen them but it has a list of patients medication on it and it should have..it has a space 
in the letter to write if there‟s been any changes to medication. So you should put there‟s been 
dose changes and things like that on it, and there‟s also a bit in the letter that says any other 
information that the GP should know. So that‟s where you could add in important things to 
look out for, what interactions they need to worry about but probably… I haven‟t written any 
myself for patients who‟ve just had transplants. I‟d probably want to give the GP a quick call 
and let them know what‟s been happening as well „cause they probably have one patient over 
their 50-year career that has had a transplant so it‟ll be entirely new to them. I quite like to 
give people just a call and let them know that this patient is getting out of the hospital and that 
they‟re on these strange medications. 
7. At the time of prescribing, do you think drug interactions are taken into consideration? 
I think if they‟re on a ward round with a pharmacist yes, but if not probably not enough. I‟m 
not aware of all of the interactions of all of the medications and if there‟s anything I‟m 
worried about I‟d look it up in the BNF or give the pharmacist a call. But probably not enough 
thought about..interactions. 
8. Would you consider drug interactions to be an important issue in the administration and 
prescribing of immuno-suppressants? 
Yeah, I think it probably is quite a big problem and in hospital everyone‟s immuno-
suppressant doses changes all the time and it‟s probably affected by other things that we‟re 
doing and giving them and certainly I don‟t probably think about it. It‟s good to have 
someone going along and checking prescriptions that you do and I think it‟s important that we 
do have someone there who looks at everything but at the time I probably don‟t think about it. 
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9. If at a point in time, the prescribing doctor is uncertain about anything regarding 
prescribing of the drug, what action do you think the doctor will take? 
Usually if there‟s something I‟m not familiar with or not happy with I speak to the senior 
doctors, the pharmacist, have a look in the BNF and see if there‟s any kind of information in 
there but generally take advice of other people. And it‟s important not to prescribe things that 
you‟re not happy with and you‟re not sure of the dose or the timings or whatever. Yeah 
(noise). I‟m sure it probably does happen but try to be as safe as you can. 
Participant 10: Transplant ward pharmacist  
Administration 
1. What do you think are high risk areas in the administration of immunosuppressant 
medication in transplant patients? (That is, are there any particular steps in the medicines 
administration process where you think things are likely to or could go wrong?) 
I think one of the biggest areas...it‟s a very specialist area. That‟s one of the drawbacks that 
there can be risks with a specialist area and those drugs are not used elsewhere so the people 
that are there, they‟d have to have that specialist knowledge about how to prescribe and 
administer those medicines and that is a risk because then, they need to be appropriately 
aware of those medicines and they won‟t come across those medicines anywhere else so it‟s a 
very select few that know about them. 
2. The nurses have a lot of responsibility and are busy around the ward. What impact do you 
think this could have on drug administration to patients?  
If they are busy then they might get interrupted and doing various things as answering the 
phone and being interrupted by another member of staff. That is risky because you know 
they‟re in the middle of something getting interrupted and that is a risk as well because they 
come back to it and they might think they‟ve done something but haven‟t or the other way 
around. As well, if they‟re really busy, they might pass a message on to someone else for 
something and that message might not get across to the appropriate person so there might be a 
risk in that as well if there‟s not the right person to speak to at that point. 
Do you think procedures are always followed? 
No I don‟t think so. 
3. After being discharged, do you think the patients go home with enough knowledge to 
safely take their immuno-suppressants in the way they were intended?  
It‟s very varied. It depends on the length of stay they‟ve had, what information they‟ve 
received from the various team. Some might get discharged before speaking to a pharmacist if 
it‟s the weekend or evening or due to the pharmacist not being around on the ward, not being 
present, not being able to speak to them, so they might get missed. The co-ordinators also 
speak to the patients but they might not have been spoken to at that point, so it just depends 
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on what information they‟ve had from various people and what information they‟ve had from 
nursing staff as well. There‟s no way to say that every patient will have the same level of 
input. 
What are the risks if patients are not educated?  
They might not know how to take their medicines appropriately and that has great 
implications in terms of them not losing the function of their organ, not complying with 
medicines, they might not know why they‟ve been prescribed something, they might not think 
it‟s important so they might miss it, and they might take double of something „cause they‟re 
not sure about medicines so there‟s always that risk that they‟ve not sure how to take them 
appropriately. 
Who educates the patient and is there a record of this? 
There‟s no record other that our official..our screening sheets that we have within pharmacy, 
that‟s just out own in-house and not an official record but we would mark down whether we 
have seen a patient first time or checked the kardex, we‟ve counselled them..that‟s for our 
own records, there‟s nothing official to say that we‟ve counselled a patient. It‟s not recorded 
anywhere officially. 
Do you know if there is any written information given to the patient? 
They are, they do the self administration scheme. When they‟re ready to start that they‟ll get 
informational leaflets of the drugs that they‟re on and that‟ll be placed in the folder for them 
to read over. They take that away with them so they have a sheet for each drug and they get a 
green booklet as well which has got a bit of information and monitoring what medicines 
they‟re on, recording what they‟re on. They take that to clinic with them as well to get it up-
dated. 
4. How important do you think patient adherence to drug regimen (compliance) is in this 
group of patients? 
Very important. The consequences are that they might lose their graft. 
5. Do you think most transplant patients do adhere to their drug regimens? If not, why do 
you think that is? 
I think most of them do. I‟d say the majority of them do but there‟s always people that don‟t 
like taking medicines for whatever reason. And maybe as you get further down the line they 
might become less compliant because they think they‟ve not had any problems and they think 
well, if I don‟t take them it won‟t matter and they you get a bit lazy and the consequences of 






1 What do you think the risks are in the prescribing of immuno-suppressants to transplant 
patients? 
Again it‟s a very specialist group of patients, a select few drugs so the risks are that there‟s 
lots of different staff members rotating so they might lose knowledge about prescribing when 
they go elsewhere, and they then come back and are not used to prescribing that. So that‟s a 
risk and as I said it‟s a select few drugs so they won‟t use these drugs elsewhere so that‟s a 
risk as well. They‟re quite specialised. 
2 Monitoring is important in the use of immuno-suppressants, and blood tests are taken 
frequently. How are the results of the blood tests taken into consideration at the time of 
prescribing? 
Well we currently do daily meetings in the morning where we will review and discuss 
patients‟ blood results in the morning so all patient results that are in in-patients will be 
discussed by the transplant team in the morning and everyone is free to attend that meeting 
and the pharmacist usually attends, the appropriate junior doctor, the consultant and his team 
will attend that ward round. So the results are reviewed daily and then it‟s a walk around ward 
round so the results are taken into consideration when they‟re prescribed. 
3 Who (which grade of doctors) does most of the prescribing of immuno-suppressants on 
the ward? 
I would say the registrar and the SHO. 
4 How important do you think it is that the GP is well informed about what happens in the 
clinic and hospital?  
Very important because they need to keep their records up to date and they need to know 
what the patient is on and what changes „cause they might be following up those changes 
to they need to know if any changes have been made. 
What are your perceptions of consequences if the GP is not being informed? 
Quite often they might be on medicines and we might start something else and the GP might 
continue prescribing something that might not be appropriate with the new medicines and if 
they‟re not aware of it, it can be a risk. So they might start therapy (noise) (…) not aware of 
so they need to know what is being changed. 
5 In your opinion, what information needs to be provided to the GP? 
A concise written information of what the patient is being discharged on and maybe a 
summary of pre-medicines that have been discontinued or changed but a concise summary of 
what they‟re being discharged on, yes so they can update their records. 
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6 What information is provided to the GP about current drug regimen at discharge, and 
eventual changes in drug regimen and how is this documented? 
At discharge they will get a copy of the discharge script listing their current medications and a 
brief summary of the discharge letter..that‟ll go to the GPs. It‟s documented through the 
discharge letters; one copy goes to the GP, one to the patient and one is filed in the patients‟ 
notes. 
7 At the time of prescribing, do you think drug interactions are taken into consideration? 
Sometimes as it depends on the experience of the prescriber and whether there‟s the presence 
of a pharmacist and their experience in that area. 
8 Would you consider drug interactions to be an important issue in the administration and 
prescribing of immuno-suppressants? 
Absolutely yes, because there‟s a lot of interactions with say tacrolimus which we use 
commonly so yeah. 
9 If at a point in time, the prescribing doctor is uncertain about anything regarding 
prescribing of the drug, what action do you think the doctor will take?  
They would usually maybe ask their senior or ask the pharmacist if they get hold..they will try 






































Questions for interviews with staff 
Administration 
1. What do you think are high risk areas in the administration of immunosuppressant 
medication in transplant patients? (That is, are there any particular steps in the medicines 
administration process where you think things are likely to or could go wrong?) 
2. The nurses have a lot of responsibility and are busy around the ward. What impact do you 
think this could have on drug administration to patients?  
Do you think procedures are always followed? 
3. After being discharged, do you think the patients go home with enough knowledge to 
safely take their immuno-suppressants in the way they were intended?  
What are the risks if patients are not educated? Who educates the patient and is there a 
record of this? 
Do you know if there is any written information given to the patient? 
4. How important do you think patient adherence to drug regimen (compliance) is in this 
group of patients? 
5. Do you think most transplant patients do adhere to their drug regimens? If not, why do 
you think that is? 
Prescribing;  
1. What do you think the risks are in the prescribing of immuno-suppressants to transplant 
patients? 
2. Monitoring is important in the use of immuno-suppressants, and blood tests are taken 
frequently. How are the results of the blood tests taken into consideration at the time of 
prescribing? 
3. Who (which grade of doctors) does most of the prescribing of immuno-suppressants on the 
ward? 
4. How important do you think it is that the GP is well informed about what happens in the 
clinic and hospital? What are your perceptions of consequences if the GP is not being 
informed? 
5. In your opinion, what information needs to be provided to the GP? 
6. What information is provided to the GP about current drug regimen at discharge, and 
eventual changes in drug regimen and how is this documented? 
7. At the time of prescribing, do you think drug interactions are taken into consideration? 
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8. Would you consider drug interactions to be an important issue in the administration and 
prescribing of immuno-suppressants? 
9. If at a point in time, the prescribing doctor is uncertain about anything regarding 




































Appendix 7: Care issues encountered most frequently by 















Care issues encountered by pharmacists 
The pharmacists on the transplant ward were asked to list the care issues that were 
encountered most frequently. The main topics that came up were that they were involved in 
the education of patients before discharge and that they felt they helped identify interactions 
of immuno-suppressants with non-immuno-suppressant related drugs. This was because the 
















































Pharmacist check-list   1 2 3 4 5 6 7 8 9 10 
Initials                       
Ward:    
     
          
type of transplant   
     
          
Number of days since transplant:   
    
            
Pharmacist:                        
1 Unnecessary drug therapy 
 a) There is no valid medical indication for the drug 
therapy at this time                     
  
b) Multiple drug products are being used for a 
condition that requires fewer drug therapies                     
  
c) Drug therapy is being taken to treat an avoidable 
adverse reaction associated with another medication                     
  d) The duration of therapy is too long                     
                        
                        
                        
2 Need for additional drug therapy 
a) A medical condition requires the initiation of drug 
therapy 
  
                
  
b) Preventive drug therapy is required to reduce the 
risk of developing a new condition                     
  
c) A medical condition requires additional 
pharmacotherapy to attain synergistic or additive 
effects                     
  
d) The duration of drug therapy is too short to 
produce the desired response                     
                        
3 Ineffective drug 
a) The drug is not the most effective for the medical 
problem                     
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  b) The formulation of the drug is inappropriate                     
  
c) The drug is not effectivefor the indication being 
treated                     
  d) The dosing interval is incorrect                     
  f) Route of administration is incorrect                     
                        
                        
4 Dosage too low 
a) The dose is too low to produce the desired 
response       
  
          
  
b) The dosage interval is too infrequent to produce 
the desired response                     
  
c) A drug-drug/food/lab/disease interaction reduces 
the amount of active drug available                     
                        
5 Adverse drug reaction 
a) The drug product causes an undesirable reaction 
that is not dose-related     
 
              
  b) A safer drug product is required due to risk factors                     
  
c) A pharmacodynamic drug-drug/food/lab/disease 
interaction causes an undesirable reaction                     
  d) The dosage regimen was changed too rapidly                     
  e) The drug product causes an allergic reaction     
 
              
  f) The drug product is contraindicated                     
                        
6 Dosage too high a) Dose is too high                     
  b) The dosing frequency is too short                     
  
c) A drug-drug/food/lab/disease interaction occurs 
resulting in a toxic reaction to the drug product                     
  d) The dose of the drug was administered too rapidly                     
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7 Inappropriate compliance a) The patient prefers not to take the medication                     
  b) The patient forgets to take the medication                     
  
c) The patient cannot swallow or self-administer the 
drug product appropriately                     
  
d) The time of dosing or the dosing interval is 
decreasing compliance.                     
                        


























































































































Appendix 10: Part of the In-patient protocol 
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